 
Protocol KP 415.S01 Amendment #[ADDRESS_994665] a need to know, with the obligation not to further disseminate 
this information . 
 
 
  May 09, 2019  
  
A Multicenter, Dose -Optimized, Open- Label Safety 
Study with KP415 in Children with Attention -
Deficit/Hyperactivity Disorder  
 
 
 
 
 
 
Protocol No:  KP415.S01 
Original Protocol dated: January 13, 2018  
Amendment #1 dated: April  16, 2018 
Amendment #2 dated: April 26, 2018 
Amendment #3 dated: May 09, 2019  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol KP415.S01 Amendment #[ADDRESS_994666] OF ABBREVIATIONS  ...................................................................................................... 7 
PROTOCOL SYNOPSIS  ............................................................................................................. 9 
1. SCHEDULE OF  EVENTS  ................................................................................................. 28 
1.1. Screening (all subjects) and Dose Optimization Phase (new subjects only)  ................ 28 
1.2. Treatment Phase (First 6 Months; All Subjects)  ........................................................... 32 
1.3. Treatment Phase (Second 6 Months), and Early Termination and Follow -Up Visits (All 
Subjects)  .................................................................................................................................... 34 
2. BACKGROUND  ................................................................................................................. 38 
2.1. Attention -Deficit Hyperactivity Disorder (ADHD)  ...................................................... 38 
2.2. KP415: A Prodrug Conjugate of d- Methylphenidate  ................................................... 38 
3. OVERVIEW OF CLINICAL STUDIES WITH KP415  ................................................. 39 
3.1. Study KP415.101 .......................................................................................................... 39 
3.2. Study KP415.109 .......................................................................................................... 40 
4. STUDY RATIONALE  ........................................................................................................ 41 
5. STUDY OBJECTIVES  ....................................................................................................... 41 
5.1. Primary Objective  ......................................................................................................... 41 
5.2. Secondary Objectives .................................................................................................... 42 
6. INVESTIGATIONAL PLAN  ............................................................................................ 42 
6.1. Study Design  ................................................................................................................. 42 
6.1.1.  Definition of “Rolled -Over Subjects” or “New Subjects” ................................................ [ADDRESS_994667] s .................................................................................. 46 
7.2.3.  Exclusion Criteria for Subjects Rolled Over from Study KP415.E01  .............................. 48 
7.2.4.  Exclusion Criteria for New Subjects  ................................................................................. 49 
7.2.5.  Eligibility Criteria for Treatment Phase  ............................................................................ 52 
8. STUDY TREATMENTS  .................................................................................................... 52 
8.1. KP415 Dose Optimization (new subjects only)  ............................................................ 52 
8.2. Study Drug Administration in the Treatment Phase  ..................................................... 53 
8.3. Treatment Assignment  .................................................................................................. 53 
8.4. Blinding......................................................................................................................... 53 
8.5. Compliance  ................................................................................................................... 53 
8.6. Study Stoppi[INVESTIGATOR_1869]  .................................................................................................... 54 
9. STUDY PROCEDURES  .................................................................................................... 54 
9.1. Screening Procedures (Visit 1A -  New Subjects Only)  ................................................ 54 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 4 of 97   May 09, 2019  
 9.2. Screening Procedures (Visit 1B -  Rolled -Over Subjects Only)  .................................... 57 
9.3. Dose Optimization Phase (Visit 2 -4; New Subjects Only)  ........................................... 59 
9.3.1.  Visit 2  ................................................................................................................................ 59 
9.3.2.  Visit 3 (Day 7 ±3 days)  ..................................................................................................... 61 
9.3.3.  Visit 4 (Day 14 ±3 days)  ................................................................................................... 62 
9.4. Treatment Phase (Visits 5 to 17; All Subjects)  ............................................................. 63 
9.4.1.  Visit 5  ................................................................................................................................ 63 
9.4.2.  Treatment During At Home Periods  ................................................................................. 65 
9.4.3.  Visit 6 through Visit 16  .................................................................................................... 65 
9.4.4.  Visit 17 (EOT Visit)  ......................................................................................................... 67 
9.5. Unscheduled Visits  ....................................................................................................... 68 
9.6. Early Termination Visit ................................................................................................ 69 
9.7. Follow -Up Visit  ............................................................................................................ 70 
9.8. End of Study (EOS)  ...................................................................................................... [ADDRESS_994668] ................................................................................ 74 
11.1.  Active Pharmaceutical Ingredients  ............................................................................... 74 
11.2.  Clinical Trial Material ................................................................................................... 74 
11.3.  Pharmaceutical Formulation  ......................................................................................... 75 
11.4.  Packaging and Labeling  ................................................................................................ 75 
11.4.1.  Dose Optimization Phase  .................................................................................................. 75 
11.4.2.  Treatment Phase  ................................................................................................................ 76 
11.5.  Dispensing and Drug Return Procedures  ...................................................................... 76 
11.5.1.  General Dispensing and Drug Return Procedures  ............................................................ 76 
11.5.2.  Dispensing in Dose Optimization Phase (Visit 2, 3, and 4)  .............................................. 76 
11.5.3.  Dispensing in Treatment Phase (Visits 5 to 16)  ................................................................ 77 
11.5.4.  Dispensing at Unscheduled Visits  .................................................................................... 77 
11.6.  Storage of Study Drug  .................................................................................................. 77 
11.7.  Study Drug Accountability  ........................................................................................... 78 
12. SAFETY AND EFFICACY ASSESSMENTS  .............................................................. 78 
12.1.  Medical History  ............................................................................................................ 78 
12.2.  Physical Examination .................................................................................................... 78 
12.3.  ADHD Diagnosis and Severity Assessments  ............................................................... 78 
12.4.  Children’s Sleep Habits Questionnaire (CSHQ)  ........................................................... 79 
12.5.  Columbia -Suicide Severity Rating Scal e (C-SSRS)  ..................................................... [ADDRESS_994669]  .............................................................................................................. 81 
12.10.  Adverse Event Assessments ......................................................................................... 82 
13. DISCONTINUATION AND REPLACEMENT OF SUBJECTS  .............................. 82 
13.1.  Withdrawal of Subjects from the Study  ........................................................................ 82 
13.2.  Replacement of Subjects  ............................................................................................... 83 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 5 of 97   May 09, 2019  
 14. STUDY ENDPOINTS  ..................................................................................................... 83 
14.1.  Safety Endpoints  ........................................................................................................... 83 
14.2.  Efficacy Endpoints  ........................................................................................................ 84 
14.3.  Sleep Behavior Endpoint  .............................................................................................. 84 
15. STATISTICAL CONSIDERATIONS  .......................................................................... 84 
15.1.  Sample Size Calculation  ............................................................................................... 84 
15.2.  Populations for Analysis  ............................................................................................... 84 
15.3.  Statistical Analyses  ....................................................................................................... 85 
15.3.1.  General Approach  ............................................................................................................. 85 
15.3.2.  Attrition  ............................................................................................................................. 85 
15.3.3.  Drug Exposure and Dosing Pattern ................................................................................... 85 
15.3.4.  Primary Endpoint Analysis (Safety in the Treatment Phase)  ........................................... 86 
15.3.5.  Secondary Endpoint Analyses (Efficacy and CSHQ in the Treatment Phase)  ................. 86 
15.3.6.  Descriptive Analyses (Safety and Efficacy in the Dose Optimization Phase)  .................. [ADDRESS_994670] Keepi[INVESTIGATOR_007]  ............................................................................................................ 93 
19.3.  Access to Source Data/Documents  ............................................................................... 93 
20. QUALITY CONTROL AND QUALITY ASSURANCE  ............................................ 93 
21. ETHICS AND GOOD CLINICAL PRACTICE COMPLIANCE  ............................. 93 
22. INSURANCE  ................................................................................................................... 93 
23. COMPLETION OF STUDY  .......................................................................................... 94 
24. STUDY ADMINISTRATIVE INFORMATION  ......................................................... 94 
24.1.  Protocol Amendments  ................................................................................................... 94 
25. REFERENCES  ................................................................................................................ 95 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 6 of 97   May 09, 2019  
 Appendix A: Instructions for Oral Administration of Study Drug  ....................................... 97 
 
  
Protocol KP415.S01 Amendment #[ADDRESS_994671]  Aspartate transaminase  
AUC  Area under the plasma concentration -time curve  
β-hCG  Beta human chorionic gonadotropin  
BLQ  Below the limit of quantification  
BMI  Body Mass Index  
CBT  Cognitive Behavioral Therapy  
CDC  Centers for Dise ase Control and Prevention  
CFR  Code of Federal Regulation s 
CGI-S Clinical Global Impressions –Severit y 
CGI-I Clinical Global Impressions –Improvement  
CI Confidence I nterval  
Cmax Maximum observed plasma concentration  
CNS  Central nervous system  
CRO  Contract Research Organization  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CSHQ  Children’s Sleep Habits Questionnaire  
CTCAE  Common Terminology Criteria for Adverse Events  
CV Coefficient of V ariation  
DEA  Drug Enforcement Agenc y 
DMDD  Disruptive Mood Dysregulation Disorder  
DSM -[ADDRESS_994672]  
Protocol KP415.S01 Amendment #[ADDRESS_994673] -square  
MedDRA  Medical Dictionary of Regulatory Activities  
MAO  Monoamine Oxidase  
MINI -KID Mini International Neuropsychiatric Interview for Children and Adolescents  
MPH  Methylphenidate  
NCE  New Chemical Entity  
ODD  Oppositional Defiant D isorder  
OTC  Over the  Counter  
PK Pharmacokinetic  
PP Per-Protocol  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
Q1 25th Percentile (1st Quartile)  
Q3 75th Percentile (3rd Quartile)  
QTcF Time between the start of the  Q wave  and the end of the  T wave  (QT interval) in 
the heart's  elect rical cycle, corrected for heart rate  with Fridericia’s formula  
SAE  Serious Adverse Event 
SAP Statistical Analysis Plan  
SOE  Schedule of Events  
SNRI  Serotonin Norepi[INVESTIGATOR_584872] I nhibitor  
SSRI  Selective Serotonin Reuptake I nhibitor  
T1/[ADDRESS_994674]  Upper Limit of Normal  
Tmax Time to achieve the maximum observed plasma concentration  
  
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 9 of 97   May 09, 2019  
 PROTOCOL SYNOPSIS  
TITLE  A Multicenter, Dose -Optimized, Open -Label Safety  Study 
with KP415 in Children with Attention- Deficit/Hyperactivity 
Disor der 
SPONSOR  KemPharm, Inc.  
PROTOCOL NUMBER  KP415.S01  
INVESTIGATIONAL 
PRODUCT  The KP415 product (capsule) contains KP415 (a prodrug of 
d-methylphenidate, d -MPH)  and immediate -release d -MPH.  
NAME [CONTACT_728321]415 prodrug is 3-(((S) -1-
carboxy -2-hydroxyethyl)carbamoyl) -1-((((R )-2-((R)-2-
methoxy -2-oxo-1-phenylethyl)pi[INVESTIGATOR_119510] -1-
carbonyl)oxy)methyl) pyridine -1-ium chloride  (single d -
methylphenidate  molecule covalently attached via a 
carbamate bond to a methylene oxide linker which in turn is 
connected to the nitrogen of the pyridi ne ring of a nicotinoyl -
serine moiety ). 
ROUTE  Oral 
NUMBER OF SITES  Approximately  20 sites in the [LOCATION_002] of America  
STUDY DESIGN  The study is a multicenter, dose -optimized, open -label safety 
study with KP415 in children with Attention -
Deficit/Hyperactivity Disorder (ADHD).  
 
Eligible subjects for the current study will be either subjects 
who completed Study KP415.E01 or new subjects who did 
not previously receive KP415. 
 
Study participation:  
  
• Rolled -Over Subjects:  For subjects rolled over from Study 
KP415.E01, the study will consist of a Screening Phase, 
Treatment Phase and a Follow -Up Visit. These subjects 
will be enrolled in the Screening Phase of the current 
study within [ADDRESS_994675] dose of study drug  in 
Study KP415.E01. The roll -over window, dose -to-dose 
between both studies (i.e., gap between the last dose in 
Study KP415.E01 [Visit 6] and the first dose in the current 
study [Visit 5]) is maximum 45 days. Subjects are allowed 
to enter Screening (Visit 1B) on the same day as the 
Follow -Up Visit in Study KP415.E01, or later . Subjects 
not rolled over from Study KP415.E01 within [ADDRESS_994676] dose of study drug, may be enrolled in the current 
study as new subjects (they will need to start with 
Screen ing followed by [CONTACT_728286] – see 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 10 of 97   May 09, 2019  
 New Subjects below). These subjects will be considered 
new subjects and will undergo all the visits and 
procedures of new subjects (starting with Visit 1A as the 
Screening Visit).  For roll -over subjects, the Investigator 
has the option to use the clinical chemistry and 
hematology results from the Follow -Up Visit in Study 
KP415.E01 (Visit 7) in lieu of collecting new blood 
samples at Screening (Visit 1B) in the current study, as 
long as the clinical chemistry  and hematology data from 
the E01 study were collected within 30 days of Screening 
(Visit 1B) in the current study. For all roll- over subjects 
who are children of childbearing potential, a blood sample 
for the measurement of a serum pregnancy test is neede d 
at Visit 1B. For other assessments required at Visit 1B (C -
SSRS, for example), the Visit 7 assessments from  the E01 
study (if collected) can be used as long as Visit 1B is 
conducted on the same day as Visit 7 in the E01 study . 
• New Subjects:  For new subjects  (not previously treated 
with KP415 during the last 45 days) , the study will consist 
of a Screening Period, a Dose Optimization Phase, a 
Treatment Phase and a Follow -Up Visit.  The study design 
and procedures  in the Treatment Phase and Follow -Up 
Visit are the same for new subjects and rolled -over 
subjects.  
 
All subjects will receive unblinded (open- label) active 
drug in all phases of the study wherein study drug is 
administered.  
 
The phases of the study are as follows:  
• Screening Period : New Subjects will undergo a screening 
period up to 30 days prior to entering into the Dose 
Optimization Phase.  Rolled -over subjects will undergo a 
screening period up to 30 days prior to entering into the 
Treatment Phase.  
• Dose Optimization Phase  (for new subject s only) : 
During the Dose Optimization Phase, subjects will be 
titrated to doses of 20, [ADDRESS_994677] dose -response in the 
opi[INVESTIGATOR_689]. 
• Treatment Phase:  Eligible subjects will receive single 
daily doses of KP415 for 360 ± 20 days , approximately 12 
months . The starting dose of KP415 given in the 
Treatment Phase will be the same as the optimized dose of 
Protocol KP415.S01 Amendment #[ADDRESS_994678] dose -
response (to either 20, 30 , or 40 mg KP415 capsules ). 
Safety,  efficacy  and sleep behavior assessments will be 
performed.  After subjects complete approximately  180 
days (approximately 6 months ) of the Treatment Phase, an 
interim analysis will be conducted to evaluate safety 
parameters . 
• Follow -Up Visit:  3 ±[ADDRESS_994679]:  
1. An interim analysis of the safety data will be 
conducted after approximately all subjects remaining 
in the study have completed 180 days  (approximately 
6 months) of treatment. After the completion of the 
interim analysis , based on the acceptance of the 
clinical and nonclinical safety database f rom the 
current study and other studies , the Sponsor may stop 
the study . Treatment in the current study will continue 
as planned while the interim analysis is conducted. If 
the decision is made to stop the study, all subjects 
remaining in the study will un dergo the EO T Visit 
(with safety evaluations including fasting safety labs 
and ECGs) and a Follow -Up Visit.  
2. After all  subjects have completed 360 days  
(approximately 1 year) of treatment .  
PRIMARY OBJECTIVE  To determine the safety and tolerability of KP415 in treating 
children with ADHD . 
SECONDARY 
OBJECTIVES  To determine efficacy  and changes in sleep behavior during  
KP415 treatment in children with ADHD . 
NUMBER OF SUBJECTS  Approximately  [ADDRESS_994680] SELECTION  
CRITERIA Inclusion Criteria for Subjects Rolled Over from Study 
KP415.E01 (at Screening Visit 1B , except when noted 
otherwise)  
1. Subjects must have completed the Double -Blind 
Treatment Phase of Study KP415.E01, and must have 
Protocol KP415.S01 Amendment #[ADDRESS_994681] dose of KP415 in Study KP415.E01  
(Visit 6)  within [ADDRESS_994682] dose in the 
current study (Visit 5 ). Subjects who completed 
Study KP415.E01 but received their last dose of 
study drug more than 45 days prior to Visit 5  are 
eligible in the current study as New S ubjects (but not 
as rolled -over subjects). Subjects who completed 
Study KP415.E01 and start the current study outside 
the 45- day roll -over window will be considered New 
Subjects and will undergo all the visits and 
procedures of new subjects  (starting with Visit 1A as 
the Screening Visit) . 
2. Subjects rolled -over from Study KP415.E01 needed 
to be at least [ADDRESS_994683] dose of study drug has been taken. Childbearing 
potential is defined as f ollows: Girls under the age of 
[ADDRESS_994684] period will be 
considered “not of child- bearing potential”. Girls of 
12 years and older (including girls who will become 
12 years or older during the study) will be considered 
“of child -bearing  potential”, even if they have not yet 
had their first period. Irrespective of age, girls who 
have had their first period, will be considered “of 
child -bearing potential”.  
4. Subject must be in general good health defined as the 
absence of any clinically relevant abnormalities as 
determined by [CONTACT_728287], vital signs, ECGs, 
medical history, and clinical laboratory values 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 13 of 97   May 09, 2019  
 (hematology, chemistry, and urinalysis) at the 
Follow -Up Visit of Study KP415.E01. If a ny of the 
hematology, chemistry, or urinalysis results are not 
within the laboratory's reference range, then the 
subject can be included only if the Investigator 
determines the deviations to be not clinically 
relevant.  
5. At least one parent/legal guardian of  the subject must 
voluntary give written permission for him/her to 
participate in the study.  
6. Subject must give written or verbal assent prior to 
study participation. For verbal assent, t he procedure 
will be documented and signed by a witness. A parent 
or guardian may not be the witness for a child's 
verbal assent document.  
7. Subject must be able and willing to wash out current 
stimulant ADHD medications (if applicable, if taking 
ADHD medications between studies) , including 
herbal medications from 5 days prior to the start of 
the Treatment Phase (Visit 5), and abstain from 
taking these to the end of the Follow -Up Visit or 
Early Termination; and wash out non- stimulant 
ADHD medications (if applicable) from 14 days prior 
to the start of the Treatment  Phase (Visit 5), and 
abstain from taking these to the end of the Follow -Up 
Visit or Early Termination.  
8. Subject, subject’s parent/legal guardian and caregiver 
(if applicable) must understand and be willing and 
able to comp ly with all study procedures and visit 
schedule. If the subject is cared for by a caregiver for 
relevant parts of any period between study visits, and 
if in this case, in the opi[INVESTIGATOR_689], the 
caregiver of the subject is more suitable for certain 
assessments, the caregiver will need to agree to the 
applicable procedures and visits.  
9. Subject, parent/legal guardian and caregiver (if 
applicable) must be able to speak and understand 
English, and be able to communicate satisfactorily 
with the Inves tigator and study coordinator.  
10. Subject must be able to swallow size [ADDRESS_994685] agrees to ta ke the contents of the capsule 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 14 of 97   May 09, 2019  
 sprinkled on a small amount of applesauce or in a 
small amount of water.  
 
Inclusion Criteria  for New Subjects (at Screening  Visit 
1A, except when noted otherwise)  
1. Subject must be at least 6 years old and less than 13 
years ol d at the start of the Dose Optimization Phase 
(Visit 2 ). 
2. Subject must have a body weight of at least [ADDRESS_994686] dose of study drug has been taken. Childbearing 
potential is defined as follows: Girls under the age of 
[ADDRESS_994687] period will be 
considered “not of child- bearing potential”. Girls of 
12 years and older (including girls who will become 
12 years or older during the study) will be considered 
“of child -bearing potential”, even if they have not yet 
had their first period. Irrespective of age , girls who 
have had their first period, will be considered “of 
child -bearing potential” . 
4. Subject must be in general good health defined as the 
absence of any clinically relevant abnormalities as 
determined by [CONTACT_728287], vital signs, ECGs, 
medical history, and clinical laboratory values 
(hematology, chemistry, and urinalysis) at Screening. 
If any of the hematology, chemistry, or urinalysis 
results are not within the laboratory's reference range, 
then the subject can be included only if the 
Investigator determines the deviations to be not 
clinically relevant.  
Protocol KP415.S01 Amendment #[ADDRESS_994688] one parent/legal guardian of the subject must 
voluntary give written permission for him/her to 
participate in the study.  
6. Subject must give written or verbal assent prior to 
study participation. For verbal assent, t he procedure 
will be documented and signed by a witness. A parent 
or guardian may not be the witness for a child's 
verbal assent document.  
7. Subject must meet Diagnostic and Statistic al Manual 
of Mental Disorders -  Fifth Edition (DSM -5) criteria 
for a primary diagnosis of ADHD (combined, 
inattentive, or hyperactive/impulsive presentation) 
per clinical evaluation and confirmed by [CONTACT_728288] (MINI -KID).  If the MINI- KID 
assessment is available from a previous study with 
KP415, it does not need to be repeated.  
8. Subject must have a score of at least 3 (mildly ill) on 
the clinician -administered Clinical Global 
Impressions –Severity (CGI -S) scale at Visit [ADDRESS_994689] be able and willing to wash out current 
stimulant ADHD medications, including herbal 
medications from 5 days  prior to the start of the Dose 
Optimization Phase (Visit 2), and abstain from taking 
these to the end of the Follow -Up Visit or Early 
Termination; and wash out non- stimulant ADHD 
medications from 14 days prior to the start of the 
Dose Optimization Phase ( Visit 2), and abstain from 
taking these to the end of the Follow -Up Visit or 
Early Termination.  
10. An ADHD- Rating Scale- 5 (ADHD -RS-5) total score 
of at least [ADDRESS_994690]’s parent/legal guardian and caregiver 
(if applicable) must understand and be willing and 
able to comply with all study procedures and visit 
schedule. If the subject is cared for by a caregiver for 
relevant parts of a scho ol day, and if in this case, in 
the opi[INVESTIGATOR_689], the caregiver of the 
subject is more suitable for certain assessments, the 
caregiver will need to agree to the applicable 
procedures and visits.  
Protocol KP415.S01 Amendment #[ADDRESS_994691], parent/legal guardian and caregiver ( if 
applicable) must be able to speak and understand 
English, and be able to communicate satisfactorily 
with the Investigator and study coordinator.  
13. Subject must be able to swallow size [ADDRESS_994692] participated 
in the KP415.E01 study previously, or unless the 
subjects agrees to take the contents of the capsule 
sprinkled on a small amount of apple sauce or in a 
small amount of water.  
 
Exclusion Criteria  for Subjects Rolled Over from Study 
KP415.E01 (at Screening Visit 1B , except when noted 
otherwise)  
1. If female, must not be pregnant or breastfeeding, and 
if of childbearing potential, must have a negative 
pregnancy test at the start of the Screening Phase 
(Visit 1B). In addition, a positive pregnancy test 
before the last dose of study drug will exclude a 
subject from further participation in the study. “Of 
childbearing potential” is defined in Section 12.9.  
2. Based on the medical history evaluated at Screenin g 
(Visit 1B ), subject with any new clinically significant 
chronic medical condition that, in the judgment of the 
Investigator, may interfere with the participant's 
ability to participate in the study, or that may affect 
safety and/or the results of the study.  
3. In the opi[INVESTIGATOR_689], subject has 
clinically significant suicidal ideation/behavior, based 
on history of attempted suicide and  the C -SSRS 
assessment at Screening or at any time before the last 
dose of study drug . 
4. Subjects are using or planning to use prohibited drugs 
during the trial as specified in the protocol.  
5. Subject has a positive urine MPH screen at Visit 5. 
6. Subject, parent/legal guardian and caregiver (if 
applicable at the Investigator’s discretion) has 
commitments during the stu dy that would interfere 
with attending study visits.  
7. Subject or subject's family anticipates a move outside 
the geographic range of the investigative site during 
the study period, or plans extended travel inconsistent 
with the recommended visit interval during study 
duration.  
Protocol KP415.S01 Amendment #[ADDRESS_994693] to participate in this 
study.  
 
Exclusion Criteria  for New Subjects (at Screening  Visit 
1A, except when noted otherwise)  
1. Subjects who have received study drug ( KP415 or 
placebo for KP415) in Study KP415.E01 during the 
[ADDRESS_994694] received KP415 in Study KP415.E01 less than 
45 days prior to the Treatment Phase are eligible to 
be enrolled in the current study as roll -overs (but not 
as new subjects).  
2. If female, must not be pregnant or breastfeeding, and 
if of childbearing potential, must have a negative 
pregnancy test at the start of the Screening Phase 
(Visit 1A). In addition, a positive pregnancy test 
before the last dose of study drug will exclude a 
subject from further participation in the study. “Of 
childbearing potential” is defined in Section 12.9.  
3. Subject with any clinically significant chronic 
medical condition that, in the judgment of the 
Investigator, may interfer e with the participant's 
ability to participate in the study.  
4. Subject has any diagnosis of bipolar I or II disorder, 
major depressive disorder, conduct disorder, 
obsessive -compulsive disorder, any history of 
psychosis, autism spectrum disorder, disruptive mood 
dysregulation disorder (DMDD), intellectual 
disability, Tourette's Syndrome, confirmed genetic 
disorder with cognitive and/or behavioral 
disturbances. Subjects with oppositional defiant 
disorder (ODD) are permitted to enroll in the study as  
long as ODD is not the primary focus of treatment, 
and, in the opi[INVESTIGATOR_689], the ODD is 
mild to moderate, and eligible subjects with ODD are 
appropriate and cooperative during Screening.  
5. Subject has generalized anxiety disorder or panic 
disorder that has been the primary focus of treatment 
at any time during the [ADDRESS_994695] has evidence of any chronic disease of the 
central nervous system (CNS) such as tumors, 
inflammation, seizure disorder, vascular disorder, 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 18 of 97   May 09, 2019  
 potential CNS related disorders that might occur in 
childhood (e.g., Duchenne Muscular dystrophy, 
myasthenia gravis, or other neurologic or serious 
neuromuscular disorders), or  history of persistent 
neurological symptoms attributable to serious head 
injury. A p ast history of febrile seizure , drug -induced 
seizure, or alcohol withdrawal seizure is allowed . 
Subject taking anticonvulsants for seizure control 
currently or within the past [ADDRESS_994696] has a current (last month) psychiatric 
diagnosis other than specific phobia, motor skills 
disorders, oppositional defiant disorder, sleep 
disorders, elimination disorders, adjustment 
disorders, learning disorders, or communication 
disorders. Subjects allowed to enroll with any of 
these DSM disorders will require written justification 
from the Investigator  documenting why the 
conditions will not interfere with participation and to 
emphasize that ADHD is the primary indication.  
8. In the opi[INVESTIGATOR_689], subject has 
clinically significant suicidal ideation/behavior, based 
on history of attempted sui cide and  the C -SSRS 
assessment at Screening or at any time before the last 
dose of study drug . 
9. Subject has any clinically significant unstable 
medical abnormality, chronic disease, or a history of 
a clinically significant abnormality of the 
cardiovascular (including cardiomyopathy, serious 
arrhythmias, structural cardiac disorders, or severe 
hypertension), gastrointestinal, respi[INVESTIGATOR_696], hepatic, 
or renal systems, or a disorder or history of a 
condition (e.g., malabsorption, gastrointestinal 
surgery) that ma y interfere with drug absorption, 
distribution, metabolism, or excretion of study drug. 
Active medical conditions that are minor or well-
controlled are not exclusionary if they do not affect 
risk to the subject or the study results. In cases in 
which the i mpact of the condition upon risk to the 
subject or study results is unclear, the medical 
monitor should be consulted. Any subject with a 
known cardiovascular disease or condition (even if 
controlled) must be discussed with the medical 
monitor during Screen ing. 
Protocol KP415.S01 Amendment #[ADDRESS_994697] has a history or presence of abnormal ECGs, 
which in the Investigator's opi[INVESTIGATOR_455992].  
11. Subject has a history of, or currently has a 
malignancy, except for non -melanomatous skin 
cancer.  
12. Subject has uncontrolled thyroid disor der as 
evidenced by [CONTACT_21923] (TSH) 
≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the 
upper limit of normal (ULN) for the reference 
laboratory at Screening.  For subjects who previously 
participated in  Study KP415.E01, this condition d oes 
not need to be re -evaluated.  
13. Subjects with a history of substance abuse or 
treatment (including alcohol) within [ADDRESS_994698] has participated in any other clinical study 
with an investigational drug/product within 90 days 
prior to Screening, or is currently participating in 
another clinic al trial, with the exception of any trial 
with KP415, as follows: Subjects who participated in 
Study KP415.E01 and completed the last dose in 
Study KP415.E01 more than 45 days before the 
Treatment Phase in the current study, are eligible as 
new subjects in  the current study. Subjects who 
completed other studies with KP415 (for example, the 
single -dose pharmacokinetic study KP415.105) may 
be enrolled in the current study as new subjects after a 
minimum [ADDRESS_994699] has taken ADHD medications from more than 
one class within 30 days prior to Screening. Subjects 
on a stable dose of one ADHD medication with 
occasional use of ADHD medications from another 
class are eligible at the d iscretion of the Investigator. 
17. Subjects with demonstrated lack of response or 
Protocol KP415.S01 Amendment #[ADDRESS_994700], parent/legal guardian and caregiver (if 
applicable at the Investigator’s discretion) has 
commitme nts during the study that would interfere 
with attending study visits.  
23. Subject or subject's family anticipates a move outside 
the geographic range of the investigative site during 
the study period, or plans extended travel inconsistent 
with the recommended  visit interval during study 
duration. 
24. Subject is, in the opi[INVESTIGATOR_689], 
unsuitable in any other way to participate in this 
study.  
 
Eligibility Criteria ( end of Dose Optimization Phase , new 
subjects only ) 
Subjects will need to meet the following additional eligibility 
criteria at the end of the Dose Optimization Phase in order to 
enter into the Treatment Phase:  
1. A reduction of ≥30% in ADHD -RS-5 from baseline 
(Visit 2) during the Dose Optimization Phase.  
2. A CG I-I score of 1 or 2 at the end of the Dose 
Optimization Phase.  
3. Acceptable tolerability of the optimized KP415 dose 
experienced during the Dose Optimization Phase.  
Rescreening  
New subjects who are screened outside the screening window 
may be rescreened for participation at a later time. New 
subjects who received any dose of study drug and are 
terminated early or are not eligible to continue in the 
Treatment Phase, are not eligible to participate later in the 
study (and will not be rescreened).  
Protocol KP415.S01 Amendment #[ADDRESS_994701], DOSE, 
AND ROUTE OF 
ADMINISTRATION The KP415 capsules contain two active pharmaceutical 
ingredients: d- methylphenidate (d -MPH) hydrochloride as the 
immediate release (IR) d -MPH component, and KP415 
prodrug as the extended release (ER) d -MPH component. In 
terms of d -MPH equivalent amounts, all capsule strengths 
contain 30% of d- MPH (IR component) and 70% of d- MPH 
from the KP415 prodrug (ER component). The total 
equivalent amount of d- MPH in each capsule strength (used 
as daily doses in this st udy), and the amounts of both APIs are 
listed in the following table.  
 
Total  
d-MPH 
dose  1 
(mg)  d-MPH  2 
 
 
(mg)  KP415  
Prodrug 3 
 
(mg)  
20 6 28 (14) 
30 9 42 (21)  
40 12 56 (28)  
1. Based on the d -MPH amount plus the equivalent amount of d -MPH as 
KP415 prodrug.  
2. The dose of d- MPH is expressed in terms of d -methylphenidate 
hydrochloride . 
3. The dose of KP415 prodrug is expressed in terms of KP415 chloride . 
The amount of d-MPH  hydrochloride  equimolar to each KP415 
prodrug dose  is listed between parentheses.  
 
The KP415 prodrug is not yet a scheduled  controlled 
substance ; however, methylphenidate is a Schedule II 
substance under the Controlled Substances Act. As a result of 
the d -MPH content i n the KP415 capsules, the drug product 
used in this study is a Schedule II product. Therefore, study 
sites are required to have the appropriate permit from the 
Drug Enforcement Agency (DEA) to receive, store, ship and 
dispense the KP415 product according t o all local, state, and 
federal regulations for Schedule II substances.  
All subjects will receive unblinded (open- label) active drug in 
all phases of the study wherein study drug is administered, as 
follows:  
• In the Dose Optimization Phase (new subjects only), 
daily treatments of 20, 30 and 40 mg open- label KP415 
capsules will be administered (one capsule/day), for the 
titration to an optimal daily KP415 dose . 
• In the Treatment Phase, daily treatments of open -label 
KP415 capsules will be administe red (one capsule/day), 
at a daily dose of KP415 that is  the same as the optimal 
dose of KP415 at the end of the Dose Optimization 
Phase, either 20, 30, or 40 mg KP415 capsules . However, 
during the Treatment Phase, the Investigator will evaluate 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 22 of 97   May 09, 2019  
 the tolerab ility and dose -response on an ongoing basis, 
and based on this evaluation, may change the dose of 
KP415. At any time, the daily oral dose of KP415 will be 
either 20, 30, or 40 mg.  
 
All study drugs will be given orally with up to 210- 240 mL 
water. Additio nal water may be given if needed . The capsule 
needs to be swallowed whole (without crushing, cutting, 
crushing, chewing, opening, or dissolving) or may be taken 
by [CONTACT_355762] a small amount 
of applesauce, or putting the conte nts in a small amount of 
water . 
ADHD 
SEVERITY/EFFICACY 
EVALUATION CRITERIA The following scales will be used to assess the changes in 
ADHD severity:  
• ADHD- Rating Scale -5 (ADHD- RS-5): The ADHD- RS-
5 is an 18- item scale (DuPaul 2016) based on Diagnostic 
and S tatistical Manual of Mental Disorders, 5th edition 
(DSM -5) (American Psychiatric Association 2013) 
criteria of ADHD that rates symptoms on a 4 -point 
scale. Each item is scored using a combination of 
severity and frequency ratings from a range of 0 
(reflect ing no symptoms or a frequency of never or 
rarely) to 3 (reflecting severe symptoms or a frequency 
of very often), so that the total ADHD -RS-5 scores 
range from 0 to 54. The 18 items can be divided into 
two 9 -item subscales: One for hyperactivity/impulsivity 
and the other for inattentiveness. Scores will be obtained 
during a clinician -directed interview with the 
parent/ guardian/caregiver  at each visit.  
• Clinical Global Impressions –Severity (CGI -S): The 
CGI-S is a clinician -rated scale that evaluates the 
severity of psychopathology (ADHD symptoms in the 
study) on a scale from 1 (not at all ill) to 7 (among the 
most severely ill) (Busner and Targum 2007).  
• Clinical Global Impressions –Improvement (CGI -I): The 
CGI-I is a clinician -rated scale that evaluates the 
improvement  of psychopathology (ADHD symptoms in 
the study) on a scale from  1 (very much improved) to 7 
(very much worse).  
During the Dose Optimization Phase (new subjects only), the 
ADHD- RS-5, CGI -I and CGI -S scale assessments are the 
main efficacy  response variables (in conjunction with 
tolerability and safety) to guide dose optimization. During 
the Treatment Phase, the ADHD -RS-5 and CGI -S scale 
assessments are the efficacy  variables to evaluate the 
changes i n ADHD severity over time, and may be used (in 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 23 of 97   May 09, 2019  
 conjunction with tolerability and safety) to adjust the dose of 
study drug.  
 
DURATION OF SUBJECT 
PARTICIPATION AND 
DURATION OF STUDY Rolled -Over Subjects:  Subjects rolled over from Study 
KP415.E01 will partic ipate in the study as outpatients for 
up to 416 days, including up to 30 days of Screening, 1 day 
for Visit 5, up to 380 days (360 ±20 days) in the Treatment 
Phase and a Follow -Up Visit up to 5 days (3 ±2 days) after 
the administration of the last dose of the Treatment Phase. 
Subjects who completed Study KP415.E01 and start the 
current study outside the 45- day roll -over window will be 
considered new subjects and will undergo all the visits and 
procedures of new subjects . The roll -over window (for 
Rolled -Over Subjects), dose -to-dose between both studies 
(i.e., gap between the last dose in Study KP415.E01 [Visit 
6] and the fist dose in the current study [Visit 5]) is 
maximum 45 days.  
 
New Subjects:  New subjects will participate in the study as 
outpatients for up to 440 days including up to 30 days of 
Screening, 1 day for Visit 2, up to 23 days (20 ±3 days) in 
the Dose Optimization Phase, 1 day for Visit 5, up to 380 
days (360 ±20 days) in the Treatment Phase and a Follow -
Up Visit up to 5 days (3 ±2 days) after the administration of 
the last dose of the Treatment Phase. 
 
If the study is stopped earlier based on the study stoppi[INVESTIGATOR_37626], all or some subjects may participate in the study for 
shorter durations than those listed above.  
MEDICATION 
RESTRICTIONS  Rolled -over s ubject s will be prohibited/limited to receive 
certain medications in the trial, as follows : 
• Stimulant ADHD medications (with the exception of  
study drug), including herbal medications, are prohibited 
from 5 days prior to the start of the Treatment Phase 
(Visit 5) to the end of the Follow -Up Visit or Early 
Termination Visit. These include: methylphenidate, 
amphetamine, Ritalin®, Ritalin® SR, Met adate® ER, 
Concerta®, dextromethylphenidate, Focalin®, 
dextroamphetamine, Dexedrine®, Adderall®. 
• Non-Stimulant ADHD medications are prohibited from 
14 days prior to the start of the Treatment Phase (Visit 5) 
to the end of the Follow -Up Visit or Early Termination 
Visit. These include: A tomoxetine, guanfacine, 
clonidine; and SSRIs such as fluoxetine  and paroxetine. 
• The following medications are prohibited from 14 days 
prior to the start of the Treatment Phase (Visit 5) to the 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 24 of 97   May 09, 2019  
 end of the Follow -Up Visit or Ear ly Termination Visit:  
o Tricyclic antidepressants.  
o Monoamine oxidase inhibitors (MAOIs).  
o Mood stabilizers (e.g., lithium, valproate, 
quetiapi[INVESTIGATOR_050]).  
o Antipsychotics (e.g., risperidone, olanzapi[INVESTIGATOR_050]).  
o Coumarin anticoagulants. 
o Anticonvulsants. 
o Halogenated anesthetics.  
o Phenylbutazone  
o Coumarin anticoagulants  
 
• Sedative hypnotics/sleep enhancers  (with the exception of 
melatonin) are prohibited from 14 days prior to the start of 
the Treatment Phase (Visit 5) to the end of the Follow -Up 
Visit or Early Termination  Visit.  
• Melatonin is allowed if subjects have taken it for more 
than 30 days before the start of the Treatment Phase (Visit 
5) and are on a stable dose. Otherwise, m elatonin is  
prohibited from 5 days prior to the start of Visit 5 to the 
end of the Follow -Up Visit or Early Termination Visit.  
 
New subjects will be prohibited/limited to receive certain 
medications in the trial, as follows:  
• Stimulant ADHD medications (with the exception of 
study drug), including herbal medications, are prohibited 
from 5 days pr ior to the start of the Dose Optimization 
Phase (Visit 2) to the end of the Follow -Up Visit or Early 
Termination Visit. These include: methylphenidate, 
amphetamine, Ritalin®, Ritalin® SR, Metadate® ER, 
Concerta®, dextromethylphenidate, Focalin®, 
dextroamphetamine, Dexedrine®, Adderall®. 
• Non-Stimulant ADHD medications are prohibited from 
14 days prior to the start of the Dose Optimization Phase 
(Visit 2) to the end of the Follow -Up Visit or Early 
Termination Visit. These include: A tomoxetine, 
guanfacine, clonidine; and SSRIs such as fluoxetine  and 
paroxetine. 
• The following medications are prohibited from 14 days 
prior to the start of the Dose Optimization Phase (Visit 2) 
to the end of the Follow -Up Visit or Early Termination 
Visit:  
o Tricyclic an tidepressants.  
o Monoamine oxidase inhibitors (MAOIs).  
o Mood stabilizers (e.g., lithium, valproate, 
quetiapi[INVESTIGATOR_050]).  
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 25 of 97   May 09, 2019  
 o Antipsychotics (e.g., risperidone, olanzapi[INVESTIGATOR_050]).  
o Coumarin anticoagulants. 
o Anticonvulsants. 
o Halogenated anesthetics.  
o Phenylbutazone  
 
• Sedative hypnotics/sleep enhancers  (with the exception of 
melatonin) are prohibited from 14 days prior to the start of 
the Dose Optimization Phase (Visit 2) to the end of the 
Follow -Up Visit or Early Termination Visit.  
• Melatonin is allowed if subjects have  taken it for more 
than 30 days before the start of the Dose Optimization 
Phase (Visit 2) and are on a stable dose. Otherwise, 
melatonin is  prohibited from 5 days prior to Visit 2  to the 
end of the Follow -Up Visit or Early Termination Visit.  
 
Allowed medic ations for all enrolled subjects:  
Medications allowed during the course of the study include 
nasal steroids, bronchodilators, acetaminophen and 
nonsteroidal anti -inflammatory medications; non -sedating 
antihistamines such as cetirizine, loratadine, and 
fexofenadine; mometasone; and approved courses of 
prescription and nonprescription medications for the 
treatment o f acute illnesses.  
 
If subjects participated in a previous study with KP415 
(including Study KP415.E01), they are allowed to take any 
medications (including ADHD medications) after 
completing the previous study with KP415 and before 
starting the current study, except for the medications and 
the time intervals specified in this protocol . 
SAFETY ENDPOINTS  • The occurrence of Treatment -Emergent Adverse Events 
(TEAEs) will be assessed starting following the first dose 
of study drug, and ending with the Follow -Up Visit or 
Early Termination Visit.  
• Physical examinations will be performed at the first visit 
(at Screening, before the first dose of study drug), after 
approximately 6 months of treatment (Visit 11), and at the 
end of the Treatment Phase (Visit 17, EOT) or at Early 
Termination.  
• Clinical laboratory tests will be performed at the first visit 
(at Screening, before the first dose of study drug), after 
approximately 6 months of treatment (Visit 11), and at the 
end of the Treatment Phase (Visit 17, EOT) or at Early 
Termination.  
• ECG parameters will be collected at the first visit (at 
Protocol KP415.S01 Amendment #[ADDRESS_994702] dose of study drug ), after 
approximately 6 months of treatment (Visit 11), and at the 
end of the Treatment Phase (Visit 17, EOT) or at Early 
Termination.  
• Vital signs, height, weight, and BMI will be collected at 
each visit.  
• A C-SSRS will be performed at each study visit.  
 
EFFICACY  ENDPOINTS  During the Dose Optimization Phase (new subjects only):  
• CGI-S will be assessed at each visit (Screening to Visit 5).  
ADHD- RS-5 will administered at Visits 2 through 5. CGI -
I will be assessed at Visits 3, 4, and 5 (since CGI -I is an 
ADH D improvement assessment, it will not be assessed at 
Screening  and at Visit 2 ). 
During the Treatment Phase (all subjects):  
• ADHD- RS-5 and CGI -S will be assessed at each visit 
(Visit 5 to Visit 17, EOT).  
 
SLEEP BEHAVIOR 
ENDPOINT  The modified, abbreviated Children’s Sleep Habits 
Questionnaire (CSHQ) will be used to assess the sleep 
behavior in the Dose Optimization Phase for new subjects 
(Visit 2) and in the Treatment Phase for all subjects (Visit 5 to 
Visit 17). The baseline will be measured before the first dose 
of study drug, at Visit 2 for new subjects and at Visit 5 for 
roll-over subjects . 
 
ANALYSIS 
POPULATIONS  • Treatment -Phase Safety Population:  All enrolled 
subjects in the Treatment Phase who received at least one 
dose of study medication in the Treatment Phase and had 
at least one post -dose safety assessment in the Treatment 
Phase.  
• Efficacy  Population:  All enrolled subj ects who 
received at least [ADDRESS_994703] the 
efficacy parameters . 
• Dose -Optimization Safety Population:  All enrolled 
subjects in the Dose Optimization Phase (“New 
Subjects”) who received at least one dose of study 
medication in the Dose Optimization Phase and had at 
least one post -dose safety assessment in the Dose 
Optimi zation Phase.  
STATISTICAL 
ANALYSES  The primary focus of the statistical analyses are the safety 
assessments during the Treatment Phase. The secondary focus 
of the statistical analyses is the efficacy  assessments during 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 27 of 97   May 09, 2019  
   the Treatment Phase. The safety and efficacy  parameters 
during the Dose Optimization Phase (for new subjects only) 
will be summarized descriptively.  
 
Primary Endpoint ( Safety  in the Treatment Phase):  
The frequencies of adverse events (AEs), changes  in clinical 
laboratory ass essments, physical examinations,  changes in 
weight, height and BMI, vital signs, ECG parameters, and the 
frequency of suicidal ideation or behavior (assessed using the 
C-SSRS) will be analyzed  in th e Treatment -Phase Safety 
Population. Th e baseline for the safety parameters will be 
measured at Visit 1A and 1B . 
 
Secondary Endpoint ( Efficacy  in the Treatment Phase):  
Changes in ADHD -RS-5, CGI -S and CSHQ will be analyzed 
in the Efficacy  Population. The baseline for ADHD -RS-5, 
CGI-S and CSHQ wi ll be measured at Visit 5 for roll- over 
subjects and at Visit 2 for new subjects.  
 
Descriptive Analyses ( Safety and Efficacy  in the Dose 
Optimization Phase):  
The safety and efficacy parameters during the Dose 
Optimization Phase (from Screening to Visit 5) will be 
summarized descriptively  in the Dose -Optimization Safety 
Population.  
 
Subgroup Analyses:  
Subgroup analyses will include safety , efficacy and CSHQ 
endpoints by [CONTACT_3885], dose (including cumulative dose), 
duration of treatment, previous treatment, age, and gender.  
STUDY PROCEDURES  The study procedures are outlined in the Schedule of 
Events ( Section 1 ).  
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 28 of 97   May 09, 2019  
 1. SCHEDULE OF  EVENTS  
1.1. Screening (all subjects) and Dose Optimization Phase (new subjects only)  
ASSESSMENTS  
NEW  
SCREE NING 
PHASE  22 
ROLLOVER  OPEN -LABEL  
DOSE OPTIMIZATION PHASE  21, 22 
(NEW SUBJECTS ONLY ) 
Study Day  -30 to 
-1 -30 to 
-1 0 1-6 
(±3 
Days)  7 
(±3 
Days)  8-13 
(±3 
Days)  14 
(±3 
Days)  15-20 
(±3 
Days)  
Visit Number  1A 1B24 2  3  4  
Parental Permission /Written or Verbal 
Assent  X X       
ADHD Diagnosis and Confirmation [ADDRESS_994704] 2 X        
Inclusion/Exclusion  X X X  X  X  
Demographics  X X       
Medical History 3 X X X      
Physical Examination  X X       
Body Weight, Height, BMI  4 X X       
Vital Signs 5 X X X  X  X  
12-Lead ECG 6 X X       
Chemistry/ Hematology/Urinalysis  
(under fasting conditions)  X X       
Urine Alcohol/Drugs of Abuse  Screen [ADDRESS_994705] 9 X X X      
C-SSRS 10 X X X  X  X  
Washout ADHD Med s 11   X      
Open -Label KP415  Dosing 12    X X X X X 
Drug Accountability & Compliance 
Assessment 13     X  X  
ADHD -RS-5 14   X  X  X  
MINI -KID 15 X        
CGI-S 16 X  X  X  X  
CGI-I 17     X  X  
CSHQ 18   X      
Adverse Events 19    X X X X X 
Concomitant Medications 20 X  X  X  X  
BMI = Body Mass Index; ECG = Electrocardiogram; MPH = methylphenidate; see footnotes for other 
abbreviations.  
 
1. ADHD Diagnosis based on the Statistical Manual of Mental Disorders -  Fifth Edition (DSM -5) 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 29 of 97   May 09, 2019  
  criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactive/impulsive  
presentation) and confirmed by [CONTACT_728289] (MINI -KID).  
2. Capsule Swallowing Test: Subjects must be able to comply with one  of the following:  
a) Subjects will take a size [ADDRESS_994706] previously participated in the KP415.E01 study.  
b) If subjects are unable to demonstrate that they can swallow size [ADDRESS_994707] rated that they are able to 
swallow size 3 capsules at Screening or any time during the study  (or have been previously 
participated in Study KP415.E01).  
3. Medical History: A complete  medical history including chronic conditions, relevant surgical 
procedures (with start date), history of drug and alcohol use.  As part of Medical History for Visit 1B 
(and with more details capture d in the database), record treatment with study drug in St udy KP415.E01 
with regards to dose, duration, date of last dose (Visit 6 in Study KP415.E01), last visit in Study 
KP415.E01 (Visit 7 in Study KP415.E01), etc.  
4. Height will be recorded in centimeters (cm) with the subject’s shoes removed. Body weight will be 
measured in kilograms (kg); subjects will remain in their normal clothing with shoes and jacket 
(and/or outer clothing) removed. 
5. Vital sign measurements will be obtained after the subject has been seated for at least 3 minutes. Vital 
signs will include si tting blood pressure (systolic and diastolic measurements), pulse rate (beats per 
minute), respi[INVESTIGATOR_697] (breaths per minute), and oral temperature. Vital signs will be collected once 
at each visit.  
6. Electrocardiogram (ECG): A [ADDRESS_994708] 3 minutes. Abnormal ECGs may be repeated for confirmation in which case only 
the repeated ECG will be recorded. The QT interval corrected for heart rate will be calculated with 
Fridericia’s formula (QTcF).  For roll -over subjects, if the Screening Visit (Visit 1B) occurs on the 
same day as the Follow -Up Visit (Visit 7) of Study KP415.E01, one ECG will be obtained to be used 
in both studies. If Visit 1B occurs later, after Visit 7 in E01, a new ECG will be obtained at Visit 1B 
as baseline for the current study.  
7. Urine Screen for Alcohol and Drugs of Abuse: Urine samples will be tested for alcohol, and drugs of 
abuse (amphetamines, methamphetamines, benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, cocaine, 
opi[INVESTIGATOR_355752]) at Screening (Visit 1A or 1B ). If the urine test is positive for any of the 
analytes at Screening, the subject will be excluded from study participation, with the exception of the 
following: Depending on a subject's current ADHD medication at Screening, the urine screen at 
Screening may test positive for ADHD medications such as amphetamines and methamphetamines. 
All ADHD medications must be washed out by [CONTACT_4838] 2  for new subjects and Visit 5 for roll -over 
subjects.  
8. Urine Screen for Methylphenidate (MPH): For new subjects, u rine samples will be tested  for MPH at 
Screening (Visit 1 A) and Visit 2. A urine dipstick (e.g., NarcoCheck®) will be used to screen for the 
presence of MPH in the urine. If a subject's current ADHD medication at Screening contains MPH, 
the urine screen at Screening  (Visit 1A, new subjects)  may test positive for MPH. A ll ADHD 
medications must be washed out by [CONTACT_4838] 2  for new subjects and Visit 5 for roll -over subjects (MPH 
urine screen mus t test negative) . 
9. Pregnancy Test: performed for female subjects of childbearing potential . A serum β -hCG pregnancy 
test will be performed at Screening. A urine pregnancy test will be performed at Visit 2. A positive 
pregnancy test at Screening or before th e last dose of study drug will exclude a subject from further 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 30 of 97   May 09, 2019  
 participation in the study. 
10. Columbia Suicide Severity Rating Scale (C -SSRS): The “Children’s Baseline/Screening” version will 
be assessed at Screening, and the “Children’s Since Last Visit” vers ion will be assessed at all other 
visits. Subjects who have , in the opi[INVESTIGATOR_689], clinically significant suicidal 
ideation/behavior, based on history of attempted suicide and the C -SSRS assessment at Screening or 
at any time before the last dose of study drug , will be exclude d from further participation in the study. 
11. All Subjects must wash out ADHD medications prior to Visit 2 . Stimulant ADHD medications (with 
the exception of study drug), including herbal medications, are prohibited from 5 days prior to Visit 2  
for new subjects and prior to Visit 5 for rolled- over subjects  to the end of the Follow -Up Visit or 
Early Termination Visit. Before or on the day during the screening period that subjects will need to 
start the washout of their AD HD medications (for example, 5 days before Visit 2 for stimulants), 
study site staff will contact [CONTACT_423]’s parent/guardian by [CONTACT_355766] 
(“washout phone call”).  
 Non-Stimulant ADHD medications are prohibited from 14 days prior  to the start of the Dose 
Optimization Phase ( Visit 2 ) to the end of the Follow -Up Visit or Early Termination Visit. Other 
prohibited medications with their associated time windows when they are prohibited are listed in the 
protocol.  
12. KP415 Dose Optimizatio n: Subjects will begin taking open -label KP415 at home the morning 
following Visit 2. The starting dose of KP415 (Days 1- 7 ±3 days) will be 30 mg/day. KP415 dose 
adjustments, if needed, will be performed at approximately weekly intervals between visits (at  Visits 
3 and 4). Actual visit dates may deviate from exactly being spaced 7 days apart such that the total 
duration of the Dose Optimization Phase is 3 weeks (21 days) ±3 days. The daily doses of KP415 
used in the Dose Optimization Phase will be 20, 30 , and 40 mg (dose optimization range of ≥20 and 
≤40 mg). At Visits 3 and 4, based on the CGI scores, interview with the parent/guardian/caregiver, 
and safety data, the Investigator will evaluate the subject’s therapeutic responses and tolerability to 
treatmen t and decide whether the current KP415 dose should be increased, decreased, or remain the 
same for the next week of dosing. If subjects experience symptoms of intolerance during the at -home 
treatment, they must contact [CONTACT_977], and, at the discre tion of the Investigator, their KP415 
dose may be adjusted before the next scheduled visit. Unscheduled visits between Visits 2, 3, and 4 
are allowed as needed, at the discretion of the Investigator.  
13. Drug Accountability & Compliance Assessment: All study drug will be recorded by [CONTACT_25733]’s 
pharmacy staff member or Investigator -delegated employee. A record of the study drug accountability 
will be prepared and kept by [CONTACT_977].  
14. ADHD -Rating Scale- 5 (ADHD -RS-5) assessment: 1 assessment at the indicated visits.  
15. Mini International Neuropsychiatric Interview for Children and Adolescents (MINI -KID): For 
confirmation of ADHD diagnosis at Screening. 
16. Clinical Global Impressions –Severity (CGI -S) scale assessment: 1 assessment at the indicated visits.  
17. Clinical Global Impressions –Improvement (CGI -I) scale assessment: 1 assessment at the indicated 
visits.  
18. Children’s Sleep Habits Questionnaire (CSHQ) assessment: 1 assessment at Visit 2.  
19. Adverse Events: To be assessed and recorded in the eCRF following the first dose of open- label drug 
(KP415), on Day 1, through either Follow -Up or Early Termination. Subject’s parent/guardian will be 
instructed to contact [CONTACT_355777]. 
20. Concomitant Med ications: new and/or changed medications and dose, medical treatments and/or 
therapi[INVESTIGATOR_728272] -Up or Early Termination.  
21. Actual visit dates in the Dose Optimization Phase may deviate from exactly being spaced 7 days apart 
such that the total duration of the Dose Optimization Phase ranges between 18 and 24 days (21 ±3 
days). Any allowed deviation (up to 3 days in total) of the targeted 21- day Dose Optimization Phase 
will be carried over into the actual days for the subsequent visits.  
22. Subjects who meet withdrawal criteria post -dose during the Dose Optimization Phase (after at least 
one dose of study drug is administered) will complete Early Termination procedures as listed in the 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 31 of 97   May 09, 2019  
 Schedule of Events in Section 1. 3. Thi s includes subjects who do not meet the eligibility criteria to 
continue in the Treatment Phase. At the discretion of the Investigator, ensuring the safety of the 
subjects, any Early Termination procedures that were already performed on the same day as par t of 
the procedures of the Dose Optimization Phase, do not need to be repeated. Subjects who withdraw 
early from the study and complete the ET procedures will not return for a Follow -Up Visit. Therefore, 
the ET Visit is the End -of-Study (EOS) for these sub jects.  
23. The procedures at Screening are different between subjects rolled over from Study KP415. E01 and 
new subjects. Therefore, the Screening Visit for roll -over subjects is designated as Visit 1B, and for 
new subjects is designated Visit 1A.  Visits 2, [ADDRESS_994709] visit of the current study, followed by [CONTACT_4838] 5 as the next visit (rolled- over subjects will not 
have Visits 2, 3 and 4).  
24. The Screening Visit for rolled -over subjects (Visit 1B) may occur on the same day as the EOS (Visit 
7, Follow -Up) in Study KP415.E01 or late r, and must occur within 30 days before Visit 5 in the 
current study . For roll -over subjects, the Investigator has the option to use the clinical laboratory 
(clinical chemistry , hematology and urinalysis)  results from the Follow -Up Visit in Study KP415.E01 
(Visit 7) in lieu of collecting new blood samples at Screening (Visit 1B) in the current study, as long 
as the clinical laboratory samples  from the E01 study were collected within 30 days prior to 
Screen ing (Visit 1B) in the current study. For all roll -over subjects who are children of childbearing 
potential, a blood sample for the measurement of a serum pregnancy test is needed at Visit 1B. For 
other assessments required at Visit 1B (C -SSRS, for example) , the Visit 7 assessments from  the E01 
study (if collected) can be used as long as Visit 1B is conducted on the same day as Visit 7 in the E01 
study. Visit 7 clinical laboratory samples collected  during KP415.E01 (also used as the Visit 1B 
results) are not  required to be collected under fasting conditions. During Visit 1B of the current study, 
the study site will document whether these samples were collected under fasting/non -fasting 
conditions, and this will be recorded in the database . 
 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 32 of 97   May 09, 2019  
 1.2. Treatment Phase ( First 6 Months; All Subjects)  
ASSESSMENTS  OPEN -LABEL  
TREATMENT PHASE 19 
Study Day  0 1-29 
(±5 
days)  30 
(±5 
days)  31-59 
(±5 
days)  60 
(±5 
days)  61-89 
(±5 
days)  90 
(±5 
days)  91-
119 
(±5 
days)  120 
(±5 
days)  121-
149 
(±5 
days)  150 
(±5 
days)  151-
179 
(±5 
days)  180 
(±5 
days)  
Visit Number  5  6  7  8  9  10  11 
Inclusion/Exclusion  X             
Medical History 1 X             
Physical Examination 2             X 
Body Weight, Height, BMI 3 X  X  X  X  X  X  X 
Vital Signs 4 X  X  X  X  X  X  X 
12-Lead ECG 5             X 
Chemistry/Hematology/Urinalysis              X 
Urine MPH Screen  (roll-overs) [ADDRESS_994710] 7 X  X  X  X  X  X  X 
C-SSRS 8 X  X  X  X  X  X  X 
Prohibited Medications 9 X X X X X X X X X X X X X 
Eligibility Criteria (new subjects) 10 X             
Enrollment in Treatment Phase 11 X             
Open -Label KP415 Dosing 12  X X X X X X X X X X X X 
Drug Accountability & Compliance 
Assessment  X 22  X  X  X  X  X  X 
ADHD -RS-5 13 X  X  X  X  X  X  X 
CGI-S 14 X  X  X  X  X  X  X 
CGI-I 15 X             
CSHQ 16 X  X  X  X  X  X  X 
Adverse Events 17 X X X X X X X X X X X X X 
Concomitant Medications 18 X  X  X  X  X  X  X 
Interim Analysis  23             X 
EOS = End of Study; ET = Early Termination; BMI = Body Mass Index; ECG = Electrocardiogram; see footnotes for other abbreviations. See 
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 33 of 97   May 09, 2019  
 Section 1.3  for all footnotes.   
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 34 of 97   May 09, 2019  
 1.3. Treatment Phase (Second 6 Months) , and Early Termination and Follow -Up Visits (All Subjects)  
ASSESSMENTS  OPEN -LABEL  
TREATMENT PHASE 19 
ET 21 
(EOS) 
FOLLOW -UP 
(EOS)  
Study Day  181-
209 
(±5 
days)  210 
 
(±5 
days)  211-
239 
(±5 
days)  240 
 
(±5 
days)  241-
269 
(±5 
days)  270 
 
(±5 
days)  271-
299 
(±5 
days)  300 
 
(±5 
days)  301-
229 
(±5 
days)  330 
 
(±5 
days)  331-
359 
(±5 
days)  360 20 
 
(±5 
days)  - 343-383 
 
(±2 days)  
19 
Visit Number   12  13  14  15  16  17 - 18 
Physical Examination 2            X X  
Body Weight, Height, BMI 3  X  X  X  X  X  X X X 
Vital Signs 4  X  X  X  X  X  X X X 
12-Lead ECG 5            X X  
Chemistry/Hematology/Urinalysis  
(under fasting conditions)             X X  
Pregnancy Test 7  X  X  X  X  X  X X X 
C-SSRS 8  X  X  X  X  X  X X X 
Prohibited Medications 9 X X X X X X X X X X X X X X 
Open -Label KP415 Dosing 12 X X X X X X X X X X X X   
Drug Accountability & Compliance 
Assessment   X  X  X  X  X  X X  
ADHD -RS-5 13  X  X  X  X  X  X   
CGI-S 14  X  X  X  X  X  X   
CGI-I 15               
CSHQ 16  X  X  X  X  X  X   
Adverse Events 17 X X X X X X X X X X X X X X 
Concomitant Medications 18  X  X  X  X  X  X X X 
EOS = End of Study; ET = Early Termination; BMI = Body Mass Index; ECG = Electrocardiogram; see footnotes for other abbreviat ions. 
  
Protocol KP415.S01 Amendment #3 CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 35 of 97   May 09, 2019  
 1. Medical History: A complete medical history including chronic conditions, relevant surgical procedures (with start date), history of drug and 
alcohol use. 
2. Physical examination at Visit  11, and at Visit 17 (EOT)  or at Early Termination (if possible).  
3. Body weight, height and BMI at each visit. Height will be recorded in centimeters (cm) with the subject’s shoes removed. Body weight will be 
measured in kilograms (kg); subjects will remain in their normal clothing with shoes and jacket (and/or outer clothing) removed. 
4. Vital sign measurements will be obtained aft er the subject has been seated for at least 3 minutes. Vital signs will include sitting blood pressure 
(systolic and diastolic measurements), pulse rate (beats per minute), respi[INVESTIGATOR_697] (breaths per minute), and oral temperature. Vital signs will 
be co llected once at each visit.  
5. Electrocardiogram (ECG): A [ADDRESS_994711] 3 minutes. Abnormal 
ECGs may be repeated for confirmation in which case only the repeated ECG will be recorded. The QT interval corrected  for heart rate will be 
calculated with Fridericia’s formula (QTcF).  
6. Urine Screen for Methylphenidate (MPH): Urine samples will be tested for MPH at Visit 5 for roll -over subjects . A urine dipstick (e.g., 
NarcoCheck®) will be used to screen for the presenc e of MPH in the urine. All ADHD medications must be washed out by [CONTACT_4838] [ADDRESS_994712] from further participation in the 
study. 
8. Columbia Suicide Severity Rating Scale (C -SSRS): The “Children’s Since  Last Visit” version will be assessed at all visits the Treatment Phase, 
and at Early Termination or Follow -Up. Subjects who have, in the opi[INVESTIGATOR_689], clinically significant suicidal ideation/behavior, 
based on history of attempted suicide and the C -SSRS assessment at Screening or at any time before the last dose of study drug , will be 
exclude d from further participation in the study. 
9. Stimulant ADHD medications (with the exception of study drug), including herbal medications, are prohibited from [ADDRESS_994713] visit of the current study, followed by [CONTACT_4838] 5 as the next visit (rolled -over subjects will not have Visits 2, 3 , and 4) . 
11. Enrollment in the Treatment Phase: Subjects able to tolerate at least 20 mg/day of KP415 and with an adequate dose -response will be enrolled 
into the Treatment Phase. The determination of tolerabilit y and adequate dose -response will be determined in Study KP415.E01 for subjects 
rolled over from Study KP415.E01  (they will need to have completed Study KP415.E01) , or at the end of the Dose Optimization Phase in the 
current study for new subjects. Subject s rolled over from Study KP415.E01 will be enrolled in the Treatment Phase of the current study (Visit 5) 
Protocol KP415.S01 Amendment #[ADDRESS_994714] dose of study drug in Study KP415.E01  (Visit 6 in Study KP415.E01) . New subjects will continue to the Treatment 
Phase im mediately after the end of the Dose Optimization Phase in the current study. Subjects not rolled over from Study KP415.E01 within [ADDRESS_994715] dose of study drug, may be enrolled in the current study as new subjects (they will need to start with Scr eening and Dose 
Optimization Phase). At the start  of the Treatment Phase  (Visit 5) , the appropriate open -label study drug to be taken at home once -a-day in the 
morning on each of the days of the Treatment Phase until the next visit will be dispensed to the  subjects.  
12. Study Drug Administration: All subjects eligible to participate in the Treatment Phase will receive non -blinded oral capsules with active KP415 
drug (one capsule). The dose level is an optimized KP415 dose of 20, 30, or 40 mg determined at the e nd of the Dose Optimization Phase in 
Study KP415.E01 for rolled- over subjects from Study KP415.E01, or as determined at the end of the Dose Optimization Phase in the current 
study for new subjects. 
Based on individual tolerability and dose -response during the Treatment Phase, at the discretion of the Investigator, the KP415 dose may be 
changed (increased or decreased, but one of the 3 dose levels of 20, 30 , or 40 mg KP415 capsules). All study drugs will be given orally. Subjects 
will take study drug (one ca psule/day) in the morning at home under supervision of their parent or legal guardian. The final dose of study drug 
will be administered on the last day of the Treatment Phase (Day 360  ±20 days; Visit 17 ). If the study is stopped earlier based on the stoppi[INVESTIGATOR_37626], the last day of the Treatment Phase (Visit 17) may occur earlier than Day 360 for some or all subjects. Study drug will be taken orally 
with up to 210 -240 mL of water. The capsule need s to be swallowed whole (without crushing, cutting, crushing, chewing, opening, or 
dissolving)  or may be taken by [CONTACT_355762] a small amount of applesauce, or putting the contents in a small 
amount of water . 
13. ADHD- Rating Scale -5 (ADHD- RS-5) assessment: 1 assessment at the indicated visits.  
14. Clinical Global Impressions–Severity (CGI -S) scale assessment: 1 assessment at the indicated visits.  
15. Clinical Global Impressions–Improvement (CGI -I) scale assessment: 1 assessment at Visit 5  for new subjects only. 
16. Children’s Sleep Habits Questionnaire (CSHQ) assessment: 1 assessment at the indicated visits.  
17. Adverse Events: To be assessed and recorded in the eCRF following the first dose of open -label drug (KP415) , through either Early Terminat ion 
or Follow -Up. Subject’s parent/guardian will be instructed to contact [CONTACT_728290]. 
18. Concomitant Medications: new and/or changed medications and dose, medical treatments and/or therapi[INVESTIGATOR_728273] 5  through 
either Follow -Up or Early Termination. 
19. To allow flexibility in scheduling visits, a ctual visit dates for individual subjects in the Treatment Phase may deviate from exactly being spaced 
30 days apart (up to 30 ±5 days  from the previous visit) such that the total duration of the Treatment Phase may be in the range of 360 ± 20 days 
(340-380 days from Visit 5 to Visit 17 ). The Follo w-Up Visit ([ADDRESS_994716] dose) therefore falls between  Day 3 43 and Day 383, but has 
its own window of ±2 days  added.  
20. The end of the Treatment Phase is on Day 360  ±20 days (Visit 17 ), after all post -dosing procedures are completed.  
21. Subjects who mee t withdrawal criteria post -dose during the Treatment Phase (after at least one dose of study drug is administered) will complete 
Early Termination procedures. At the discretion of the Investigator, ensuring the safety of the subjects, any Early Terminati on procedures that 
were already performed on the same day as part of the procedures of the Treatment Phase, do not need to be repeated. Subjects  who withdraw 
early from the study and complete the ET procedures will not return for a Follow -Up Visit. Therefore , the ET Visit is the End -of-Study (EOS) 
for these subjects.  
22. Drug Accountability & Compliance Assessment: All study drug will be recorded by [CONTACT_25733]’s pharmacy staff member or Investig ator-
Protocol KP415.S01 Amendment #[ADDRESS_994717] of the study drug accountability wil l be prepared and kept by [CONTACT_728291] (including drug accountability at Visit [ADDRESS_994718] week of the Dose Optimization Phase , 
by [CONTACT_160516]) . 
23. An interim analysis of the safety data will be conducted after approximately all subjects remaining in the study have complet ed 180 days  
(approximately 6 months) of treatment. After the completion of the interim analysis, based on the acceptance of the cli nical and nonclinical 
safety database from the current study and other studies, the Sponsor may stop the study. Treatment in the current study will  continue as planned 
while the interim analysis is conducted. If the decision is made to stop the study, all subjects remaining in the study will undergo the EOT Visit 
(with safety evaluations including fasting safety labs and ECGs) and a Follow Up Visit.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 38 of 97   May 09, 2019  
 2. BACKGROUND  
2.1. Attention -Deficit Hyperactivity D isorder (ADHD)  
ADHD is a common neurobehavioral disorder that occurs in 6- 8% of children and 4- 5% of adults 
worldwide (Wilens  2008). The [ADDRESS_994719] common and effective therapeutics for the treatment of ADHD are CNS 
stimulants , which  contain amphetamine or methylphenidate  (MPH) . Amphetamine -containing 
products include brand names such as Adderall®, Dexedrine®, Dextrostat®, and Vyvanse®. 
Methylphenidate containing products include Metadate®, Concerta®, Daytrana®, Ritalin®, 
Methylin®, Quilivant®, and Focalin®. Positive effects on behavior and academic productivity are 
well established for stimulant medications such as MPH  (Wilens  and Biederman 1992) . Several 
studies have shown that, in children with ADHD, MPH improves cl assroom functioning, notably 
by [CONTACT_728292], accuracy and 
improvement in teacher ratings. In addition, MPH has been shown  to improve performance in 
children for several  cognitive tasks, incl uding measures of attention and memory . 
2.2. KP415: A  Prodrug  Conjugate of d -Methylphenidate  
KemPharm is developi[INVESTIGATOR_728274]415 as an extended release  (ER)  prodrug of d- threo -MPH HCl. 
Chemically, KP415 consists of a single d -threo -MPH molecule covalently attached via a carbamate 
bond to a methylene oxide linker which in turn is connected to the nitrogen of the pyridine ring of 
a nicotinoyl -serine moiety. The covalent linkage makes KP415  a new chemical entity (NCE). 
Results from preliminary in vivo studies in rats have shown that the prodrug has unique 
pharmacokinetic (PK) properties that suggest it will have reduced intranasal and intravenous abuse 
potential.  
As a prodrug, KP415 represents a potential abuse- deterrent form of MPH with abuse- deterrent 
properties that are imparted at the molecular level. Some of the KP415 attributes that make it worthy 
of further development are highlighted below:  
• KP415 has negligible pharmacological activit y at key receptors that are responsible for the 
efficacy of d -MPH for the treatment of ADHD.  
• When administered intranasally or intravenously  in rats , KP415  resulted in  d-MPH  plasma 
concentrations that are significantly reduced when compared to  d-MPH HCl . 
• KP415 exhibits chemical stability when subjected to certain hydrolytic conditions with the 
intention to extract methylphenidate . 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 39 of 97   May 09, 2019  
 3. OVERVIEW OF CLINICAL STUDIES  WITH KP415  
The p harmacology, metabolism and toxicology of methylphenidate are well established (Challman 
and Lipsky 2000, Leonard 2004). Methylphenidate is a CNS stimulant approved for the treatment 
of ADHD and narcolepsy. Methylphenidate inhibits the reuptake of dopamine  and norepi[INVESTIGATOR_238], 
increased dopaminergic and noradrenergic activity in the prefrontal cortex may explain its efficacy 
in ADHD.  
Common side effects of methylphenidate include nervousness, agitation, anxiety, sleep problems 
(insomnia), stomach pain, decreased appetite, weight loss, nausea, vomiting, dizziness, palpi[INVESTIGATOR_814], 
headache, vision problems, increased heart rate, increased blood pressure, sweating, skin rash, 
psychosis, and numbness, tingling, or cold feeling in hands or feet.  When abused, methylphenidate 
produces toxicity similar to other CNS stimulant overdoses  (Morton  and Stockton  2000). Supra -
therapeutic doses have shown to cause delirium, hallucination s, bruxism (jaw -grinding), and 
trismus (jaw clenching)  (Morton and Stockton  2000). 
3.1. Study KP41 5.101  
This Phase 1 proof -of-concept trial (Study KP415.101) was designed to assess the PK of 32 mg of 
KP415 API (liquid, dissolved in water) compared with 36 mg of Concerta® (tablet) after oral 
administration under fasted conditions. Twenty -four (24) healt hy adult volunteers were enrolled in 
this open- label, single -dose, two- treatment, two -period PK trial. Dosing levels in each treatment 
were not molar equivalent amounts of d- MPH: 36 mg Concerta® contained approximately 12% 
more d -MPH than 32 mg of the KP41 5 prodrug API (standalone KP415).  
KP415 API [INVESTIGATOR_728275] d -MPH into the bloodstream which is consistent 
with previously collected preclinical data. After KP415 API [INVESTIGATOR_728276], the mean peak 
concentration (C max) of d -MPH was 2 .9 ng/mL at a median T max of 8 hr compared to 8.0 ng/mL at 
6 hr after Concerta®. 
The mean systemic exposure (AUC 0-last) for d -MPH was 44 ng•hr/mL after KP415 API [INVESTIGATOR_728277] 97 ng•hr/mL after Concerta® dosing. The mean total systemic exposure (AUC 0-inf) for d -
MPH was 100 ng•hr/mL after KP415 API [INVESTIGATOR_728278] 102 ng•hr/mL after Concerta® dosing. 
The mean terminal elimination plasma half -life (T 1/2) of d -MPH was 25 hr after KP415 API [INVESTIGATOR_728277] 4 hr after Concerta®. 
After oral dosing of standalone KP415, it appears that that there is rapid absorption of prodrug 
followed by [CONTACT_728293] d- MPH resulting in a gradual onset followed by a slow extended release 
of d-MPH. The later T max and longer T 1/2 for d -MPH after KP4 15 dosing indicate that KP415 as a 
prodrug of d -MPH has extended -release (ER) properties that support a once -per-day dosing 
schedule for an ADHD indication. The ER properties inherent in the KP415 prodrug molecule can 
subsequently provide sustained d- MPH e xposure, as desired for a once -per-day treatment of ADHD 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 40 of 97   May 09, 2019  
 in adults. No l -MPH levels were detected after KP415 dosing and very low l -MPH levels were 
measured after Concerta® dosing. 
Both treatments were generally well -tolerated. There were no apparent chang es in vital signs and 
ECG parameters between treatments. Safety laboratory values were approximately the same after 
the treatment phase versus those measured at Screening.  
3.2. Study KP415.109  
This Phase 1 open- label PK study included a treatment group wherein healthy adult volunteers were 
dosed for 7 days with oral daily doses of 12 mg d -MPH API (immediate release comp onent ) and 
[ADDRESS_994720] 
dose that will be used in the current protocol.  
The mean d -MPH plasma concentrations on Day 7 of Study KP415.109 are presented in Figure 1. 
The mean d -MPH trough concentration (C min; pre-dose on Day 7) w as 3.3 ng/mL and the mean d -
MPH peak concentration (C max on Day 7 ) was 20 .9 ng/mL at a median T max of 1.5 hr. The mean 
systemic exposure over the dosing interval (AUC 0-24hr) for d -MPH was 208  ng•hr/mL and the mean 
terminal elimination plasma half -life (T 1/2) of d -MPH was 8. 9 hr. The mean accumulation ratios 
(Day 7/Day 1 ratios) for C min, C max and AUC 0-24hr were 1.3 1, 1.20  and 1.3 4, respectively. The 
combination of 70%/30% KP415/d -MPH resulted in early peak d -MPH exposure followed by 
[CONTACT_12814] d- MPH exposure , as desired for chronic, once -per-day treatment of  ADHD in a pediatric 
population . The efficacy and safety of this combination in children 6 -12 years old with ADHD will 
be studied in the study presented in this protocol.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 41 of 97   May 09, 2019  
 Figure 1: Mean (N=10) d- Methylphenidate (d -MPH) Concentrations after the 7th Oral Daily 
Dose of 12 mg d- MPH and 56 mg KP415 Prodrug (Together Equivalent to 40 mg d- MPH)  
 
4. STUDY RATIONALE  
The safety of KP415 has been investigated in pharmacokinetic studies with healthy adult vol unteers 
after daily oral doses of up to 7 days. In addition, the efficacy and safety in children 6 -12 years old 
with ADHD is being investigated in Study KP415.E01. Study KP415.E01 is a multicenter, dose -
optimized, double -blind, randomized, placebo- controll ed, parallel efficacy laboratory classroom 
study with KP415 with daily oral KP415 administration up to 4 weeks. The rationale of the current 
study is to investigate the safety and tolerability of daily oral KP415 doses for a longer duration. I n 
addition, t he current study will also  determine  the efficacy  and sleep behavior  of KP415 in treating 
children with ADHD . For ease of enrollment and to extend the duration of dosing already available 
from Study KP415.E01, the study population will include  subjects rolled over from Study 
KP415.E01 (A Multicenter, Dose- Optimized, Double -Blind, Randomized, Placebo -Controlled, 
Parallel Efficacy Laboratory Classroom Study with KP415 in Children with Attention-
Deficit/Hyperactivity Disorder ). 
5. STUDY OBJECTIVES  
5.1. Primary Objective  
To determine the safety and tolerability of KP415 in treating children with ADHD . 

Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 42 of 97   May 09, 2019  
 5.2. Secondary Objectives  
To determine  the efficacy  and changes in sleep behavior during  KP415 treatment in children with 
ADHD.  
6. INVESTIGATIONAL PLAN 
6.1. Study Design  
The study is a multicenter, multiple -dose, dose-optimized, open -label safety study with KP415 
administered orally in children with Attention -Deficit/Hyperactivity Disorder (ADHD).  
Approximately 20 sites in the [LOCATION_002] of America will take part  in the study.  
6.1.1.  Definition of “R olled -Over Subjects”  or “N ew Subjects”  
Eligible subjects  for the current study will be either “Rolled -Over Subjects”  or “N ew S ubjects” , 
defined as follows : 
• Rolled -Over Subjects  are those who successfully completed Study KP415.E01 and rolled 
over (i.e., received first dose in the current study) within [ADDRESS_994721] dose of study 
drug in Study KP415.E01. The roll -over window (for Rolled- Over Subjects), dose -to-dose 
between b oth studies (i.e., gap between the last dose in Study KP415.E01 [Visit 6] and the 
first dose in the current study [Visit 5]) is maximum 45 days. For roll -over subjects, the 
Investigator has the option to use the clinical chemistry and hematology results fr om the 
Follow -Up Visit in Study KP415.E01 (Visit 7) in lieu of collecting new blood samples at 
Screening (Visit 1B) in the current study, as long as the clinical chemistry and hematology 
data from the E01 study were collected within 30 days of Screening (V isit 1B) in the current 
study . For all roll -over subjects who are children of childbearing potential, a blood sample 
for the measurement of a serum pregnancy test is needed at Visit 1B. For other assessments 
required at Visit 1B (C -SSRS, for example), the Visit 7 assessments from the E01 study (if 
collected) can be used as long as Visit 1B is conducted on the same day as Visit 7 in the E01 
study.  
• New Subjects  are those who did not participate in Study KP415.E01  or completed the last 
dose in Study KP415.E01 more than [ADDRESS_994722] dose in the current study . 
Subjects who completed other studies with KP415 (for example, the single -dose 
pharmacokinetic study KP415.105) may be enrolled in the current study as new subjects 
after a minimum [ADDRESS_994723] dose of KP415 and Screening in the 
current study.  
Rolled -over subjects and new subjects will need to  meet the ir respective inclusion/exclusion criteria 
listed in Section 7.2.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 43 of 97   May 09, 2019  
 6.1.2.  Study Participation  
The study visits, treatment and procedures leading up to the Treatment Phase are different for rolled -
over and new subjects, as follows:  
• Rolled -Over Subjects: Fo r subjects rolled over from Study KP415.E01, the study will 
consist of a Screening Phase, Treatment Phase and a Follow -Up Visit. These subjects will 
be enrolled in the Treatment Phase of the current study (first dose at Visit 5) within [ADDRESS_994724] dose of study drug in Study KP415.E01. The roll -over window (for Rolled 
Over Subjects), dose -to-dose between both studies (i.e., gap between the last dose in Study 
KP415.E01 [Visit 6] and the first dose in the current study [Visit 5]) is maximum 45 days . 
Subjects are allowed to enter Screening (Visit 1B) on the same day as the Follow -Up Visit 
in Study KP415.E01 , or later . Subjects not rolled over from Study KP415.E01 within [ADDRESS_994725] dose of study drug, may be enrolled in the current study as new subjects 
(they will need to start with Screening followed the by [CONTACT_728294] – see New 
Subjects below). These subjects will be considered New Subjects and will undergo all the 
visits and procedures of New Subjects (starting with Visit 1A as the Screening Visit). For 
roll-over subjects, the Investigator has the option to use the clinical chemistry and 
hematology results from the Follow -Up Visit in Study KP415.E01 (Visit 7) in lieu of 
collecting new blood samples at Screening (Visit 1B) in the current study, as long as the 
clinical chemistry and hematology data from the E01 study were collected within 30 days 
of Screening (Visit 1B) in the current study. For all roll -over subjects who are female 
subjects  of childbearing potential, a blood sample  for the measurement of a serum pregnancy 
test is needed at Visit 1B. For other assessments required at Visit 1B (C -SSRS, for example), 
the Visit 7 assessments from the E01 study (if collected) can be used as long as Visit 1B is 
conducted on the same day a s Visit 7 in the E01 study . 
• New Subjects:  For new subjects, the study will c onsist of a Screening Period, a  Dose 
Optimization Phase, a Treatment Phase and a Follow -Up Visit.   
The study design and pr ocedures in the Treatment Phase, the Follow -Up Visit and t he Early 
Termination Visit are the same for new subjects and rolled -over subjects.  
6.1.3.  Study Phases and Treatment  
All subjects will receive unblinded (open -label) active drug (KP415 capsules) in all phases of 
the study wherein study drug is administered.  
The p hases of the study are as follows:  
• Screening Period : New Subjects will undergo a screening period up to 30 days prior to 
entering into the Dose Optimization Phase. Rolled -over subjects will undergo a screening 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 44 of 97   May 09, 2019  
 period up to 30 days prior to entering into the Treatment Phase.  
• Dose Optimization Phase (for new subject s only) : During the Dose Optimization Phase, 
subjects will be titrated to doses of 20, [ADDRESS_994726] dose -response in the opi[INVESTIGATOR_689].  
• Treatment Phase: Eligible subjects will receive single daily oral doses of KP415 for 
approximately 360 days (approximately 12 months ), or for a shorter duration if the study is 
stopped earlier  (see Section 8.6 for the study stoppi[INVESTIGATOR_004]) . The starting dose of KP415 
given in the Treatment Phase will be the same as the optimized dose of KP415 determined 
and used in Study KP415.E01 for rolled- over subjects , or determined at the end of the Dose 
Optimization Phase for new subjects. During the Treatment Phase, the dose of KP415 may 
be changed based on individual tolerability and best dose -response (to either 20 , 30 or 40 
mg KP415  capsules ). Safety,  efficacy  and sleep behavior assessments will be per formed.  
• Follow -Up Visit : 3 ±[ADDRESS_994727] dose of the Treatment Phase, 
subjects will enter a Follow -Up Visit to evaluate safety parameters.  
6.2. Study Duration  
Rolled -Over Subjects:  Subjects rolled over from Study KP415.E01 will partic ipate in the study as 
outpatients for up to 416 days, including  up to 30 days of Screening, 1 day for Visit 5, up to 3 80 
days ( 360 ±20 days) in the Treatment Phase and a Follow -Up Visit up to 5 days (3 ±2 days) after 
the administration of the last dose of the Treatment Phase. Subjects who completed Study 
KP415.E01 and start the current study outside the 45- day roll -over window will be co nsidered new 
subjects and will undergo all the visits and procedures of new subjects.  
New Subjects:  New subjects will participate in the study as outpatients for up to 4 40 days including 
up to 30 days of Screening, 1 day for Visit 2, up to 23 days (20 ±3 d ays) in the Dose Optimization 
Phase, 1 day for Visit 5, up to 3 80 days ( 360 ±20 days) in the Treatment Phase and a Follow -Up 
Visit up to 5 days (3 ±2 days) after the administration of the l ast dose of the Treatment Phase.  
If the study is stopped earlier ba sed on the study stoppi[INVESTIGATOR_004]  (see Section 8.6), all or some 
subjects may participate in the study for shorter durations than those listed above.  
7. SUBJECT SELECTION  
7.1. Number of Subjects  
Approximately  250 subjects will be enrolled in the Treatment Phase of the study. Subjects will be 
rolled over from Study KP415.E01 and to reach the targeted number of subjects, new subjects will 
be enrolled  as well . Subjects who fail Screening and new subjects who terminate early during the 
Dose Optimization Phase may be rep laced. Subjects who terminate early in the Treatment Phase 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 45 of 97   May 09, 2019  
 will not be replaced.  
7.2. Study Population  
Subjects  rolled over from Study KP415.E01 or new subjects  with ADHD who meet the 
inclusion/exclusion criteria listed below.  See Section 6.1.1  for the definiti ons of rolled -over subjects 
and new subjects.  
7.2.1.  Inclusion Criteria for Subjects Rolled Over from Study KP415.E01  
(To be evaluated at Screening Visit 1B , except when noted otherwise ) 
A subject will be eligible for inclusion in the study if all the following c riteria apply:  
 
1. Subjects must have completed the Double -Blind Treatment Phase of Study KP415.E01, and 
must have received the last dose of KP415 in Study KP415.E01 (Visit 6) within [ADDRESS_994728] dose in the current study (Visit 5). Subjects who completed Study 
KP415.E01 but received their last dose of study drug more than 45 days prior to Visit 5 are 
eligible in the current study as New Subjects (but not as rolled -over subjects). Subjects who 
completed Study KP415.E01 and start the current study  outside the 45- day roll -over window 
will be considered New Subjects and will undergo all the visits and procedures of new 
subjects (starting with Visit 1A as the Screening Visit).  
2. Subjects rolled -over from Study KP415.E01 needed to be at least [ADDRESS_994729] dose of study drug has been taken. 
“Of childbearing potential” is defined in Section 12.9. Acceptable form s of birth control are 
listed in Secti on 10.[ADDRESS_994730] be in general good health defined as the absence of any clinically relevant 
abnormalities as determined by [CONTACT_728295], vital signs, ECGs, medical history, and clinic al laboratory values 
(hematology, chemistry, and urinalysis) at the Follow -Up Visit of Study KP415.E01. If any 
of the hematology, chemistry, or urinalysis results are not within the laboratory's reference 
Protocol Amendment #[ADDRESS_994731] one parent/legal guardian of the subject must voluntary give written permission for 
him/her to participate in the study.  
6. Subject must give written or verbal assent prior to study participation. For verbal assent, the 
procedure will be documented and signed by a witness. A parent or guardian may not be the 
witness for a child's verbal assent document.  
7. Subject must be able and willing to wash out current stimulant ADHD medications (if 
applicable , if taking ADHD medications between studies ), including herbal medications 
from 5 days prior to the start of the Treatment Phase (Visit 5), and abstain from taking these 
to the end of the Follow -Up Visit or Early Termination; and wash ou t non -stimulant ADHD 
medications (if applicable) from 14 days prior to the start of the Treatment  Phase (Visit 5), 
and abstain from taking these to the end of the Follow -Up Visit or Early Termination.  
8. Subject, subject’s parent/legal guardian and caregiver (if applicable) must understand and 
be willing and able to comply with all study procedures and visit schedule. If the subject is 
cared for by a caregiver for relevant parts of any period between study visits, and if in this 
case, in the opi[INVESTIGATOR_689], the caregiver of the subject is more suitable for 
certain assessments, the caregiver will need to agree to the applicable procedures and visits.  
9. Subject, parent/legal guardian and caregiver (if applicable) must be able to speak and 
understand English, and be able to communicate satisfactorily with the Investigator and 
study coordinator.  
10. Subject must be able to swallow size [ADDRESS_994732] participated in the  KP415.E01 study 
previously, or unless the subjects agrees  to take the contents of the capsule sprinkled on a 
small amount of applesauce or in a small amount of water.  
7.2.2.  Inclusion Criteria for New Subjects  
(To be evaluated at Screening  Visit 1 A, except when noted otherwise)  
A subject will be eligible for inclusion in the study if all the following criteria apply:  
1. Subject must be at least 6 years old and less than 13 years old at the start of the Dose 
Optimization Phase ( Visit 2 ). 
2. Subject must have a body weight of at least 21 kg at Screening.  
Protocol Amendment #[ADDRESS_994733] dose of study drug has been taken. 
“Of childbearing potential” is defined in Section 12.9. Acceptable form s of birth control are 
listed in Section 10.[ADDRESS_994734] be in general good health defined as the absence of any clinically relevant 
abnormalities as determined by [CONTACT_3433] e Investigator based on physical and neurological 
examinations, vital signs, ECGs, medical history, and clinical laboratory values 
(hematology, chemistry, and urinalysis) at Screening. If any of the hematology, chemistry, 
or urinalysis results are not within the laboratory's reference range, then the subject can be 
included only if the Investigator determines the deviations to be not clinically relevant.  
5. At least one parent/legal guardian of the subject must voluntary give written permission for 
him/her to participate in the study.  
6. Subject must give written or verbal assent prior to study participation. For verbal assent, the 
procedure will be documented and signed by a witness. A parent or guardian may not be the 
witness for a child's verbal assent document . 
7. Subject must meet Diagnostic and Statistical Manual of Mental Disorders -  Fifth Edition 
(DSM -5) criteria for a primary diagnosis of ADHD (combined, inattentive, or 
hyperactive/impulsive presentation) per clinical evaluation and confirmed by [CONTACT_445596] (MINI -KID).  If the 
MINI -KID assessment is available from a previous study with KP415, it does not need to 
be repeated . 
8. Subject must have a score of at least 3 (mildly ill) on the clinician -administered Clinical 
Global Impressions –Severity (CGI -S) scale  at Visit [ADDRESS_994735] be able and willing to wash out current stimulant ADHD medicatio ns, 
including herbal medications from 5 days prior to the start of the Dose Optimization Phase 
(Visit 2 ), and abstain from taking these to the end of the Follow -Up Visit or Early 
Termination; and wash out non -stimulant ADHD medications from 14 days prior t o the start 
of the Dose Optimization Phase ( Visit 2 ), and abstain from taking these to the end of the 
Follow -Up Visit or Early Termination.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 48 of 97   May 09, 2019  
 10. An ADHD- Rating Scale- 5 (ADHD- RS-5) total score o f at least [ADDRESS_994736]’s parent/legal guardian and caregiver (if applicable) must understand and 
be willing and able to comply with all study procedures and visit schedule. If the subject is 
cared for  by a caregiver for relevant parts of a school day, and if in this case, in the opi[INVESTIGATOR_18959], the caregiver of the subject is more suitable for certain assessments, the 
caregiver will need to agree to the applicable procedures and visits.  
12. Subject, parent/legal guardian and caregiver (if applicable) must be able to speak and 
understand English, and be able to communicate satisfactorily with the Investigator and 
study coordinator.  
13. Subject must be able to swallow size [ADDRESS_994737] participated in the KP415.E01 study 
previously, or unless the subjects agrees to take the contents of the capsule sprinkled on a 
small amount of apple sauce or in a small amount  of water . 
7.2.3.  Exclusion Criteria for Subjects R olled Over from Study KP415.E01  
(To be evaluated at Screening Visit 1B , except  when noted otherwise ) 
A subject who meets any of the following exclusion criteria will not be enrolled into the study:  
1. If female, must not be pregnant or breastfeeding, and if of childbearing potential, must have 
a negative pregnancy test at the start of the Screening Phase (Visit 1B). In addition, a 
positive pregnancy test before the last dose of study drug will exclude a  subject from further 
participation in the study. “Of childbearing potential” is defined in Section 12.9.  
2. Based on the medical history evaluated at Screening (Visit 1B), subject with any new 
clinically significant chronic medical condition that, in the jud gment of the Investigator, 
may interfere with the participant's ability to participate in the study, or that may affect 
safety and/or the results of the study. 
3. In the opi[INVESTIGATOR_689], subject has clinically significant suicidal 
ideation/behavior, based on history of attempted suicide and the C -SSRS assessment at 
Screening or at any time before the last dose of study drug . 
4. Subjects are using or planning to use prohibited drugs during the trial as specified in the 
protocol. 
5. Subject has a positive urine MPH screen at Visit 5.  
Protocol Amendment #[ADDRESS_994738], parent/legal guardian and caregiver (if applicable at the Investigator’s discretion) 
has commitments during the study that would interfere with attending study visits.  
7. Subject or subject's family anticipates a move out side the geographic range of the 
investigative site during the study period, or plans extended travel inconsistent with the 
recommended visit interval during study duration. 
8. Subject is, in the opi[INVESTIGATOR_689], unsuitable in any other way to par ticipate in 
this study.  
7.2.4.  Exclusi on Criteria for New Subjects  
(To be evaluated at Screening  Visit 1A , except when noted otherwise)  
A subject who meets any of the following exclusion criteria will not be enrolled into the study:  
1. Subjects who have received stu dy drug (KP415 or placebo for KP415)  in Study KP415.E01  
during the [ADDRESS_994739] received KP415 in 
Study KP415.E01 less than 45 days prior to the Treatment Phase  are eligible to be enrolled 
in the current study as roll -overs (but not as new subjects).  
2. If female, must not be pregnant or breastfeeding, and if of childbearing potential, must have 
a negative pregnancy test at the start of the Screening Phase (Visit 1A). In addition, a 
positive pregnancy test be fore the last dose of study drug will exclude a subject from further 
participation in the study. “Of childbearing potential” is defined in Section 12.9.  
3. Subject with any clinically significant chronic medical condition that, in the judgment of the 
Investig ator, may interfere with the participant's ability to participate in the study.  
4. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct 
disorder, obsessive -compulsive disorder, any history of psychosis, autism spectrum 
disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, Tourette's 
Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances. 
Subjects with oppositional defiant disorder (ODD) are permitted to enroll in the s tudy as 
long as ODD is not the primary focus of treatment, and, in the opi[INVESTIGATOR_689], 
the ODD is mild to moderate, and eligible subjects with ODD are appropriate and 
cooperative during Screening.  
5. Subject has generalized anxiety disorder or pa nic disorder that has been the primary focus 
of treatment at any time during the [ADDRESS_994740] has evidence of any chronic disease of the central n ervous system (CNS) such as 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 50 of 97   May 09, 2019  
 tumors, inflammation, seizure disorder, vascular disorder, potential CNS related disorders 
that might occur in childhood (e.g., Duchenne Muscular dystrophy, myasthenia gravis, or 
other neurologic or serious neuromuscular disorde rs), or history of persistent neurological 
symptoms attributable to serious head injury. A past history of febrile seizure, drug -induced 
seizure, or alcohol withdrawal seizure is allowed. Subject taking anticonvulsants for seizure 
control currently or with in the past [ADDRESS_994741] has a current (last month) psychiatric diagnosis other than specific phobia, motor 
skills disorders, oppositional defiant disorder, sleep disorders, elimination disorder s, 
adjustment disorders, learning disorders, or communication disorders. Subjects allowed to 
enroll with any of these DSM disorders will require written justification from the 
Investigator documenting why the conditions will not interfere with participatio n and to 
emphasize that ADHD is the primary indication.  
8. In the opi[INVESTIGATOR_689], subject has clinically significant suicidal 
ideation/behavior, based on a history of attempted suicide and the C -SSRS assessment at 
Screening or at any time before the last dose of study drug . 
9. Subject has any clinically significant unstable medical abnormality, chronic disease, or a 
history of a clinically significant abnormality of the cardiovascular (including 
cardiomyopathy, serious arrhythmias, structural cardiac disorders, or severe hypertension), 
gastrointestinal, respi[INVESTIGATOR_696], hepatic, or renal systems, or a disorder or history of a condition 
(e.g., malabsorption, gastrointestinal surgery) that may interfere with drug absorption, 
distribution, metabolism, or excretion of study drug. Active medical conditions that are 
minor or well -controlled are not exclusionary if they do not affect risk to the subject or the 
study results. In cases in which the impact of the condition upon risk to the subject or study 
results is unclear, the medical monitor should be consulted. Any subject with a known 
cardiovascular disease or condition (even if controlled) must be discussed with the medical 
monitor during Screening  
10. Subject has a history or presence of abnorma l ECGs, which in the Investigator's opi[INVESTIGATOR_728279].  
11. Subject has a history of, or currently has a malignancy, except for non -melanomatous skin 
cancer.  
12. Subject has uncontrolled thyroid disorder as evidenced by [CONTACT_21923] 
(TSH) ≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the upper limit of normal (ULN) 
for the reference laboratory at Screening.  For subjects who previously participated in  Study 
KP415.E01, this condition does not need to be re -evaluated.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 51 of 97   May 09, 2019  
 13. Subjects with a history of substance abuse or treatment (including alcohol) within [ADDRESS_994742] shows evidence of substance or alcohol use or is currently using tobacco or other 
nicotine -containing products, or has a positive urine alcohol or urine drug screen at 
Screening. Subjects with a positive urine drug screen (including urine MPH screen) at 
Screening may be allowed to continue in the study, provided that the Investigator determines 
that the positive test is a result of taking prescribed medicat ions, and subject is willing to 
wash out the current medication as required. 
15. Subject has participated in any other clinical study with an investigational drug/product 
within 90 days prior to Screening, or is currently particip ating in another clinical tria l, with 
the exception of any trial with KP415 , as follows:  Subjects who participated i n Study 
KP415.E01 and  completed the last dose in Study KP415.E01 more than 45 days before the 
Treatment Phase in the current study , are eligible as new subjects in the cu rrent study . 
Subjects who completed other studies with KP415 (for example, the single -dose 
pharmacokinetic study KP415.105) may be enrolled in the current study as new subjects 
after a minimum [ADDRESS_994743], parent/legal guardian and caregiver (if applicable at the Investigator’s discretion) 
has commitments duri ng the study that would interfere with attending study visits.  
23. Subject or subject's family anticipates a move outside the geographic range of the 
Protocol Amendment #[ADDRESS_994744] to participate in 
this study.  
7.2.5.  Eligibility Criteria for Treatment Phase  
(To be evaluated at the e nd of the Dose Optimization Phase , for new subjects only ) 
Subjects will need to meet the following additional eligibility criteria at the end of the Dose 
Optimization Phase in order to enter into the Treatment Phase:  
1. A reduction of ≥30% in ADHD -RS-5 from baseline ( Visit 2 ) at the end of the  Dose 
Optimization Phase.  
2. A CGI -I score of 1 or 2 at the end of the Dose Optimization Phase.  
3. Acceptable tolerability of the optimized KP415 dose experienced during the Dose 
Optimization Phase.  
8. STUDY TREATMENTS  
8.1. KP415 Dose Optimization  (new subjects only)  
In the Dose Optimization Phase, daily treatments of 20, 30 and 40 mg open- label KP415 capsules 
will be administered (one capsule/day  in the morning ), for the titration to an optimal daily KP415 
dose based on tolerability and best individual dose -response in the opi[INVESTIGATOR_689] . Study 
drug will be taken orally in the morning at home or, at the visit days, may be taken at the study site. 
The capsule needs to be swallowed whole , or may be taken by [CONTACT_728296] a small amount of applesauce, or putting the contents in a small amount of water . See 
Appendix A  for detailed instructions. Any of the methods of administration may be used on any 
day of the study . 
Subjects will begin taking open- label KP415  at home the morning following Visit 2. The starting 
dose of KP415 (Days 1 -7 ±3 days ) will be 30 mg /day. KP415  dose adjustments, if needed, will be 
performed at approximately weekly intervals  between visits (at Visits 3  and 4). Actual visit dates 
may deviate from exactly being spaced 7 days apart such that the total duration of the Dose 
Optimization Phase ranges betw een 18 and 24 days (21 ±3 days) . The daily doses of KP415  used 
in the Dose Optimization  Phase will be 20 , 30, and 40 mg (dose o ptimization range of ≥ 20 and ≤ 40 
mg). At Visit s 3 and 4, based on the CGI  scores , interview with the parent /guardian/ caregiver , and 
safety data, the I nvestigator will evaluate the subject’s therapeutic responses  and tolerability to 
treatment and decide whether the current KP415  dose should be increased, decreased, or remain the 
Protocol Amendment #[ADDRESS_994745] the clinical site, and, at the discretion of the Investigator, their 
KP415 dose may be adjusted before the next scheduled visit. Unscheduled visits between Visits 2, 
3, 4, a nd 5 are allowed as needed, at the discretion of the Investigator.  
At Visit 5  (start of the Treatment Phase) , the Investigator will evaluate the eligibility criter ia (see 
Section 7.2.5) for continuation into the Treatment Phase. For subjects eligible for t he Treatment 
Phase, the optimal daily KP415 dose will be used as the  daily KP415 dose during  the Treatment 
Phase . 
8.2. Study Drug Administration in the Treatment Phase  
All subjects  will be administered one unblinded KP415 capsule once daily in the Treatment Pha se. 
The dose of KP415 will be determined by [CONTACT_728297]415  at the end of the Dose 
Optimization Phase, either 20, 30,  or 40 mg/day KP415.  Study drug  will be taken orally in the 
morning at home  or, at the visit days, may be taken at the study site. The capsule needs to be 
swallowed whole, or may be taken by [CONTACT_355762] a small amount of 
applesauce, or putting the contents in a small amount of water. See Appendix A  for detailed 
instructions. Any of the methods of administration may be used on any day of the study . 
8.3. Treatment Assignment  
Dose  Optimization Phase  (new subjects only) : All eligible subjects will start on a dose of 30 
mg/day open- label KP415  and the KP415  dose w ill be titrated to either 20 , 30 or 40 mg /day based 
on tolerability and best individual dose -response in the opi[INVESTIGATOR_689].  
Treatment Phase  (all subjects) : Rolled -over subjects from  Study KP415.E01, and new subjects 
who completed the Dose Opt imization Phase (and passed the eligibility criteria for the Treatment 
Phase, Section 7.2.5) , will be enrolled  at Visit 5 (start of the Treatment  Phase)  for treatment with 
the optimized dose of  KP415 capsules . During the Treatment Phase, at the Investigator’ discretion, 
based on individual tolerability and dose response, the daily dose of KP415 may be changed to any 
of the allowed dose levels (20, 30, or 40 mg/day). 
8.4. Blinding  
This is an open -label study. Study treatments will not be blinded . 
8.5. Compl iance  
All study drug will be recorded by [CONTACT_25733]’ s pharmacy staff member or Investigator -delegated 
employee. A record of the study drug accountability  will be prepared and kept by [CONTACT_977].  
Acceptable  Compliance is defined  as 80 -100% (inclusive) . If Compliance between subsequent 
scheduled visits of the Treatment Phase  (Visits 6 through 16)  is outside this acceptance range, or 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 54 of 97   May 09, 2019  
 cannot be determined (when, for example, the subject did not return unused study drug), the 
Investigator or de signee will counsel the parent/legal guardian. If a  subject is noncompliant more 
than once, the Investigator will discuss the subject’s noncompliance with the Medical Monitor.  
8.6. Study Stoppi[INVESTIGATOR_728280],  whichever comes first:  
1. An interim analysis of the safety data will be conducted after approximately all subjects 
remaining in the study have completed 180 days  (approximately 6 months) of treatment. 
After the completion of the interim analysis, based on the acceptance of the clinical and 
nonclinical safety database from the current study and other studies, the Sponsor may stop 
the study. Treatment in the current study will continue as planned while the interim analysis 
is conducted. If the decision is made  to stop the study, all subjects remaining in the study 
will undergo the EO T Visit (with safety evaluations including fasting safety labs and ECGs) 
and a Follow -Up Visit.  
2. After all subjects have completed 360 days  (approximately 1 year) of  treatment.  
9. STUDY PROCEDURES  
For all subjects, the study will include a Screening Phase, Treatment Phase and a Follow -Up Visit.  
For new subjects only, after the Screening Phase and before entering the Treatment Phase, there 
will be  a Dose Optimization Phase . Subjects rolled over from Study KP415.E01  (within the 45- day 
window) will have a Screening Visit followed by  a Treatment  Phase  (no Dose Optimization Phase)  
because eligibility assessments and dose optimization were completed in Study KP415.E01. A table 
with the Schedule of Events ( SOE) representing the required testing procedures to be performed is 
included in Section [ADDRESS_994746] of these procedures and assessments:  
9.1. Screening Procedures  (Visit 1A - New Subjects Only) 
The procedures at Screening are different between subjects rolled over from Study KP415. E01 and 
new subjects. Therefore, the Screening Visit for new s ubjects is designated Visit 1A (current 
section), and for roll -over subjects , is designated as Visit 1B  (see Section 9.2).  
Subjects will complete the screening v isit (Visit 1 A) within 30 days of starting the Dose 
Optimization Phase  (Visit 2 ). Prior to conducting any study -related activities  including screening 
procedures , written  or verbal  assent  and the Health Insurance Portability and Accountability Act 
(HIPAA) authorization must be  signed and dated by [CONTACT_7071]/legal guardian . 
The following procedures  will be performed at the Screening Visit: 
1. Permission  and HIPAA authorization by [CONTACT_174964]/legal guardian of the subject . 
Protocol Amendment #[ADDRESS_994747] . For verbal assent, the procedure will be 
documented and signed by a witness. A parent or guardian may not be the witness for 
a child's verbal assent document.  
3. ADHD Diagnosis and Confirmation based on the Statistical Manual of Me ntal 
Disorders - Fifth Edition (DSM -5) criteria for a primary diagnosis of ADHD 
(combined, inattentive, or hyperactive/impulsive presentation) and confirmed by [CONTACT_728298] (MINI -
KID).  
4. Perfo rm the clinician -administered Clinical Global Impressions –Severity (CGI -S) 
scale assessment.  Subject s must have a CGI-S score of at least 3 (mildly ill) for further 
study participation.  
5. Subject demographics including date of birth, sex, race, and ethnicity . 
6. Administer a size 3 placebo capsule orally with up to 240 mL of water (Capsule 
Swallowing Test).  The capsule may not contain any active drug substance. Subjects 
must be able to easily swallow the size [ADDRESS_994748] previously participated in the 
KP415.E01 study , or for subjects who are planning to take the study drug as the  capsule 
contents sprinkled over a small amount of applesauce  or added to a small amount  of 
water.  Subjects will be instructed how to take the study medication while at home. See 
Appendix A  for detailed instructions.  
7. Review of  inclusion/exclusion criteria to determine study  eligibility . 
8. Record medi cal history  including chronic conditions, relevant surgical procedures 
(with start date), medications, and history of alcohol and  recreational drug use.  
9. A complete physical  exam ination . 
10. Body weight, height, and BMI.  
11. Vital signs after a minimum of [ADDRESS_994749] (respi[INVESTIGATOR_697], pulse  rate, blood 
pressure, and oral temperature) . 
12. Perform the  Columbia Suicid e Severity Rating S cale ( C-SSRS ) assessment , 
“Children’s Baseline/Screening” version.  Subjects with clinically significant suicidal 
ideation/behavior, in the opi[INVESTIGATOR_689] , based on a history of attempted 
suicide and the C -SSRS assessment , will be exclude d from enrollment in the study, and 
further evaluation and/or preventive intervention steps for suicidal behavior will be 
taken, at the discretion of the Investigator.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 56 of 97   May 09, 2019  
 13. 12-lead e lectrocardiogram  (ECG)  after subject  has been  in supi[INVESTIGATOR_19636]  a 
minimum  of 3 minutes . 
14. Clinical laboratory  tests (chemistry, hematology and urinal ysis) will be obtained  under 
fasting conditions . Clinical l aboratory m easurements may be repeated at the discretion 
of the Investigator.  
15. At Screening, u rine samples will be tested for alcohol  and drugs of abuse 
(amphetamines, methamphetamines, benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, 
cocaine, opi[INVESTIGATOR_355752]). If the urine test is positive for alcohol  or drugs 
of abuse at Screening, the subject will be excluded from study participat ion, with the 
exception of the following: Depending on a subject's current ADHD medication at 
Screening, the urine screen at Screening may test positive for ADHD medications such 
as amphetamines  and metha mphetamines . All ADHD medication s must be washed out  
by [CONTACT_4838] [ADDRESS_994750] will be excluded from study 
participation, with the exception of the following: Depending on a subject 's current 
ADHD medication at Screening, the urine screen at Screening may test positive for 
methylphenidate. All ADHD medication s must be washed out by [CONTACT_4838] 2.  
17. Serum β -human chorionic gonadotropin ( β-hCG ) pregnancy test  for al l female subjects 
of childbearing potential . See Section 12.[ADDRESS_994751] from further participation in the study. 
18. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_728281].  
After subject s complete  the s creening procedures and are  considered eligible to take part in the 
clinical study , they will be instructed to return to the clinic at  Visit 2 to begin the  Dose Optimization 
Phase.  In addition, if applicable, they will be given  the date on which to begin wash out of any 
ADHD and other medications prior to Visit 2 . See Section 1 0.2 for the medications that are 
prohibited and their associated time frames, including the days that they are prohibited before V isit 
2, i.e., washout days for subjects taking the medications.  
Before or on the day during the screening period that subjects will need to start the washout of their 
ADHD medications  (for example, 5 days before Visit 2 for stimulants ), study site staff w ill contact 
[CONTACT_423] ’s parent /guar dian by [CONTACT_728299] (“washout phone call”) . 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 57 of 97   May 09, 2019  
 Rescreening:  New subjects who are screened outside the screening window may be rescreened for 
participation at a later time. New subj ects who received any dose of study drug and are terminated 
early or are not eligible to continue in the Treatment Phase, are not eligible to participate later in 
the study (and will not be rescreened).  
9.2. Screening Procedures ( Visit 1B - Rolled -Over Subjects  Only)  
The procedures at Screening are different between subjects rolled over from Study KP415.E 01 and 
new subjects. Therefore, the Screening Visit for roll ed-over subjects is designated as Visit 1B  
(current section) , and for new subjects is designated Vis it 1A  (see Section 9.1 ). 
Screening Window:   
The Screening Visit for rolled -over subjects (Visit 1B) may occur on the same day as the EOS (Visit 
7, Follow -Up) in Study KP415.E01,  or later, and must occur within 30 days before Visit 5 in the 
current study. The roll -over window (for Rolled- Over Subjects), dose -to-dose between both studies 
(i.e., gap between the last dose in Study KP415.E01 [Visit 6] and the fist dose in the current study 
[Visit 5]) is maximum [ADDRESS_994752] (HIPAA) authorization must be 
signed and dated by [CONTACT_3040]/legal guardian.  
The following procedures  will be performed at the Screening Visit: 
1. Permission and HIPAA authorization by [CONTACT_174964]/legal guardian of the subject.  
2. Written or verbal assent by [CONTACT_423]. For verbal assent, the procedure will be 
documented and signed by a witness. A parent or guardian may not be the witness for 
a child's verbal assent document.  
3. Subject demographics including date of birth, sex, race, and ethnicity. 
4. Review of inclusion/exclusion criteria to determine study eligibility , including the 
successful completion of Study KP415.E01.  
5. Record medical history including chronic conditions, relevant surgical procedures 
(with start date), medications, and history of alcohol and recreational drug use.  
6. As part of Medical History (and wi th more details capture d in the database), record 
treatment with study drug in Study KP415.E01 with regards to dose, duration, date of 
last dose (Visit 6 in Study KP415.E01), last visit in Study KP415.E01 (Visit 7 in Study 
KP415.E01), etc. 
7. A complete physi cal examination.  
Protocol Amendment #[ADDRESS_994753] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature).  
10. Perform the C -SSRS assessment, “Children’s Baseline/Screening ” version. Subjects 
with clin ically significant suicidal ideation/behavior, i n the opi[INVESTIGATOR_689] , 
based on a history of attempted suicide and the C -SSRS assessment , will be excluded  
from enrollment in the study, and further evaluation and/or preventive intervention 
steps  for suicidal behavior will be taken, at the disc retion of the Investigator.  For roll -
over subjects, if the Screening Visit (Visit 1B) occurs on the same day as the Follow -
Up Visit (Visit 7) of Study KP415.E01, one C -SSRS will be obtained to be used in bot h 
studies. If Visit 1B occurs later, after Visit [ADDRESS_994754] has been in supi[INVESTIGATOR_19636] a minimum of 3 minutes.  For 
roll-over subjects, if the Screening Visit (Vi sit 1B) occurs on the same day as the 
Follow -Up Visit (Visit 7) of Study KP415.E01, one ECG will be obtained to be used 
in both studies. If Visit 1B occurs later, after Visit 7 in E01, a new ECG will be obtained 
at Visit 1B as baseline for the current stud y. 
12. Clinical laboratory tests (chemistry, hematology and urinalysis) will be obtained under 
fasting conditions  (or under non- fasting conditions for the special case explained 
below) . For roll -over subjects, the Investigator has the option to use the clinical 
laboratory  results from the Follow -Up Visit in Study KP415.E01 (Visit 7) in lieu of 
collecting new blood samples at Screening (Visit 1B) in the current study, as long as 
the clinical labora tory samples  from the E01 study were collected within 30 days prior 
to Visit 1B . If clinical laboratory measurements from V isit 7 of study KP415.E01 are 
being utilized, then fasting is not required; however, the site must record whether the 
samples were co llected under fasting/non- fasting conditions. Clinical laboratory 
measurements may be repeated at the discretion of the Investigator.  
13. At Screening, urine samples will be tested for alcohol and drugs of abuse 
(amphetamines, methamphetamines, benzodiazepi[INVESTIGATOR_1651] , barbiturates, cannabinoids, 
cocaine, opi[INVESTIGATOR_355752]). If the urine test is positive for alcohol or drugs 
of abuse at Screening, the subject will be excluded from study participation, with the 
exception of the following: Depending on a subjec t's current ADHD medication at 
Screening, the urine screen at Screening may test positive for ADHD medications such 
as amphetamines and methamphetamines. All ADHD medications must be washed out 
by [CONTACT_4838] 5 (rolled -over subjects will not have Visits 2, 3 and 4) , and the urine test must 
be negative for further study participation . 
Protocol Amendment #[ADDRESS_994755] visit of 
the current study, followed by [CONTACT_4838] 5 as the next visit (rolled- over sub jects will not have Visits 2, 
3 and 4).  
If applicable, roll -over subjects will be given the date on which to begin wash out of any ADHD 
and other medications prior to Visit 5. See Section 10.1 for the medications that are prohibited and 
their associated time frames, including the days that they are prohibited before Visit 5, i.e., washout 
days for subjects taking the medications.  
Before or on the day during the screening period that subjects will need to start the washout of their 
ADHD medications (for exam ple, 5 days before Visit 5 for stimulants), study site staff will contact 
[CONTACT_423]’s parent/guardian by [CONTACT_355766] (“washout phone call”).  
Rescreening:  Subjects that successfully completed Study KP415.E01 but are unable to be screened 
within the screening window for r oll-over subjects  may be screened as new subjects.  Rolled -over 
subjects who received any dose of study drug in the current study but are terminated early, are not 
eligible to participate later in the study (and wil l not be rescreened).  
9.3. Dose Optimization Phase  (Visit 2 -4; New Subjects Only ) 
Subjects who meet the inclusion/exclusion criteria during Screening, will enter into the Dose 
Optimization Phase (Visit s 2, 3, and 4). The s ubjects will undergo the following proc edures  during 
these visits . 
9.3.1.  Visit 2  
The following procedures  will be performed at Visit 2 : 
1. Review of inclusion/exclusion criteria to determine whether subjects continue to meet 
Protocol Amendment #[ADDRESS_994756] (respi[INVESTIGATOR_697], pulse  rate, blood 
pressure, and oral temperature) . 
4. Perform the C-SSRS , “Children’s Since Last Visit” version . Subjects with clinically 
significant suicidal ideation/behavior, i n the opi[INVESTIGATOR_689] , based on the C -
SSRS assessment , will be exclude d from further participation in the study , and further 
evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the 
discretion of the Investigator.  
5. Perform the ADHD -RS-5 score  assessment  (baseline assessment) . Subjects needs to 
have an ADHD -RS-[ADDRESS_994757] 5 days . 
6. Perform the clinician -administered CGI -S scale assessment  (baseline assessment ). 
Subject s must have a CGI-S score of at least 3 (mildly ill) for further study participation. 
For subjects requiring washout of ADHD medications, this criterion refers to a score 
following  washout of at least 5 days . 
7. Perform the CSHQ.  The Investigator or designee will fill in the CSHQ questionnaire 
based on an interview with the parent/guardian/caregiver . For subjects requiring 
washout of ADHD medications , the scoring will be based on the s ubject’s sleep behavior 
on the days after washout for at least 5 days before Visit 2 . 
8. Urine Screen for MPH: Urine samples will be tested for MPH at Visit 2  for new subjects. 
A urine dipstick (e.g., NarcoCheck®) will be used to screen for the presence of MPH in 
the urine. All ADHD medications must be washed out by [CONTACT_4838] 2  (MPH urine screen 
must test negative) . New subjects with a positive MPH urine screen at Visit [ADDRESS_994758] from further participation in the study.  
10. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
11. Provide subject with the starting dose of 30 mg KP415 capsules  to begin the Dose 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 61 of 97   May 09, 2019  
 Optimization Phase (Days 1 -7 ±3 days ). KP415 dose adjustments, if needed, will be 
performed at approximately weekly intervals  between visits (at Visits 3  and 4) . Actual 
visit dates may deviate from exactly being spaced 7 days apart such that the total 
duration of the Dose Optimization Phase ranges betw een 18 and 24 days (21 ±3 days) . 
Subjects will be instructed to take study drug every morning while at home under the 
supervision of their parent/legal guardian/caregiver.  The capsule needs to be swallowed 
whole , or may be taken by [CONTACT_355762] a small amount of 
applesauce, or putting the contents in a small amount of water . See Appendix A  for 
detailed instructions. Any of the methods of administration may be used on any day of 
the study . 
9.3.2.  Visit 3  (Day 7  ±3 days ) 
The following procedures  will be performed at Visit 3 : 
1. Record the number of r eturned and administered capsules of unblinded study drug for 
drug accountability and compliance  (See Section 8.5 ). 
2. Review of inclusion/exclusion criteria to determine whether subjects continue to meet 
study eligibility.  
3. Update medical history . 
4. Vital signs  after a minimum of [ADDRESS_994759] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature) . 
5. Perform the C -SSRS, “Children’s Since Last Visit” version . Subjects with clinically 
significant suicidal ideation, in the opi[INVESTIGATOR_689] , based on the C -SSRS 
assessment , will be exclude d from further participation in the study , and further 
evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the 
discretion of the Investigator.  
6. Perform the ADHD- RS-5 score assessment.  
7. Perform the clinician -administered CGI -S scale assessment.  
8. Perform the CGI -I scale assessment.  
9. KP415 dosing and dose adjustments, if needed, will be performed at wee kly intervals ± 
3 days. At Visit 3  based on the CGI, interview with the parent /guardian/ caregiver , and 
safety data, the I nvestigator will evaluate the subject’s therapeutic responses and 
tolerability to treatment, and decide whether the current KP415  dose should be 
increased, decreased, or remain the same for the next  week of titration . At any day during 
Protocol Amendment #[ADDRESS_994760]’s parent/guardian will be 
instructed to contact [CONTACT_728300] . 
11. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
9.3.3.  Visit 4  (Day 14 ±3 days)  
The following procedures  will be performed at Visit 4 : 
1. Record the number of returned and administered capsules of unblinded study drug for 
drug accountability and compliance . 
2. Review of inclu sion/exclusion criteria to determine whether subjects continue to meet 
study eligibility.  
3. Update medical history . 
4. Vital signs after a minimum of [ADDRESS_994761] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature) . 
5. Perform the C-SSRS, “Children’s Since Last Visit” version . Subjects with clinically 
significant suicidal ideation, in the opi[INVESTIGATOR_689] , based on the C -SSRS 
assessment , will be exclude d from further participation in the study , and further 
evaluation and/ or preventive intervention steps for suicidal behavior will be taken, at the 
discretion of the Investigator.  
6. Perform the ADHD -RS-5 score assessment.  This assessment may be obtained by [CONTACT_285252] 48 hours before the visit.  
7. Perform the clinician -administered CGI -S scale assessment.  This assessment may be 
obtained by [CONTACT_1382] 48 hours before the visit . 
8. Perform the CGI -I scale assessment.  This assessment may be obtained by [CONTACT_1382] 
48 hours before the visit.  
9. KP415 dosing and dose a djustments, if needed, will be performed at wee kly intervals 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 63 of 97   May 09, 2019  
 ±3 days . At Visit 4, based on the CGI, interview with the parent /guardian/ caregiver , and 
safety data, the I nvestigator will evaluate the subject’s therapeutic responses and 
tolerability to treatment, and decide whether the current KP415  dose should be 
increased, decreased, or remain the same for the next week of titration. At any day during 
the Dose Optimization Phase, the daily dose will be either 20, 30 or 40 mg KP415  
capsules . Subjects will be instructed to take study drug every morning while at home 
under the supervision of their parent/legal guardian/caregiver. Additional water may be 
given if needed. The capsule needs to be swallowed whole , or may be taken by 
[CONTACT_728301] a small amount of applesauce, or putting the 
contents in a small amount of water . See Appendix A  for detailed instructions. Any of 
the methods of administration may be used on any day of the study . 
10. Assessment  and review of Adverse Events,  and the s ubject’s parent/guardian will be 
instructed to contact [CONTACT_728300] . 
11. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
9.4. Treatment Phase (Visits  5 to 17; All Subjects) 
Subjects who meet the inclusion/exclusion criteria will enter into the Treatment Phase (Visits  5-
17). The s ubjects will undergo the following procedures  during these visits.  
9.4.1.  Visit [ADDRESS_994762] taken ADHD medications (other than study drug in Study 
KP415.E01) between KP451.E01 and Visit [ADDRESS_994763] the parent/guardian [ADDRESS_994764] abstain of taking 
study drug on the 5 days before Visit 5.  
The following procedures will be performed at  Visit 5 : 
1. If applicable, r ecord the number of returned and administered caps ules of unblinded 
study drug for drug accountability and compliance . This only applies to new subjects 
who received study drug at home between Visits 4 and 5, as part of the Dose 
Optimization Phase.  
2. Review of inclusion/exclusion criteria to determine wheth er subjects continue to meet 
study eligibility.  
 
3. Update medical history.  
Protocol Amendment #[ADDRESS_994765] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature).  
6. Urine Screen for MPH  (roll-over subjects only) : Urine samples will be tested for MPH 
at Visit 5 for roll -over subjects. A urine dipstick (e.g., NarcoCheck®) will be used to 
screen for the presence of MPH in the urine. All ADHD medications must be washed 
out by [CONTACT_4838] 5 for rol l-over subjects (new subjects wil l not be tested since they will have 
receive d study drug in the preceding Dose Optimization Phase).  Roll-over s ubjects with 
a positive MPH urine screen at Visit [ADDRESS_994766] from further participation in the study.  
8. Perform the C -SSRS  assessment , “Children’s Since Last Visit” version . Subjects with 
clinically significant suicidal ide ation/behavior, in the opi[INVESTIGATOR_689] , based 
on the C -SSRS assessment , will be exclude d from further participation in the study , and 
further evaluation and/or preventive intervention steps for suicidal behavior will be 
taken, at the discretion of the Investigator.  
9. Perform the ADHD- RS-5 score assessment.  
10. Perform the clinician -administered CGI -S scale assessment.  
11. For new subjects only, perform the CGI -I scale assessment.  This assessment at the end 
of the Dose Optimization Phase is used to evaluate eligibility criteria for the Treatment 
Phase of new subjects (see Section 7.2.5 ). 
12. Perform the CSHQ. The Investigator or designee will fill in the CSHQ questionnaire 
based on an interview with the parent/guardian/caregiver. The scoring will be b ased on 
the subject’s sleep behavior on the days before Visit 5 (and after washout of ADHD 
medications, if applicable). This assessment will be used as the baseline to assess sleep 
behavior.  
13. For new subjects only, t he Investigator will evaluate the eligibility criteria (see Section 
7.2.5) based on the data from the Dose Optimization Phase for continuation into the 
Treatment Phase. For subjects eligible for the Treatment Phase, the previously 
determined optimal daily KP415 dose will be used as the daily KP415 dose in the 
Treatment Phase.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 65 of 97   May 09, 2019  
 14. Eligible subjects will be enrolled in the Treatment Phase, and their  appropriate dose of 
unblinded study drug  (KP415 capsules)  to be taken at home once -a-day in the morning 
on each of the following 30 days (Days 1- 30 ±5 days) will be dispensed to the subjects. 
Subjects will be instructed to take study drug every morning while at home under the 
supervision of their parent/legal guardian/caregiver. The capsule needs to be swallowed 
whole , or may be taken by [CONTACT_728302] c ontents of the capsule over a small amount of 
applesauce, or putting the contents in a small amount of water . See Appendix A  for 
detailed instructions. Any of the methods of administration may be used on any day  of 
the study . 
15. Assessment  and review of  Adverse Events , and the s ubject’s parent/guardian will be 
instructed to contact [CONTACT_728300] . 
16. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014] . 
9.4.2.  Treatment During At Home Periods  
On days of the Treatment Phase between visits, subjects will take unblinded study drug at home 
under supervision of parent or legal guardian. Study drug will be taken daily in the morning while 
at home . The capsule needs to be swallowed whole , or may be taken by [CONTACT_728303] a small amount of applesauce, or putting the contents in a small amount of water . 
See Appendix A  for detailed instructions. Any of the methods of administration may be used on 
any day of the study . 
Subject’s parent/guardian will contact [CONTACT_728304] . Subjects will need to adhere to all medication restrictions and general restrictions 
(see Section 10 ). 
9.4.3.  Visit 6 through Visit 16  
The following procedures will be performed during each of the Visits 6 -16 (inclusive) , except when 
noted otherwise:  
1. Record the number of returned and administered capsules of unblinded study drug for 
drug accountability and compliance  (See Section 8.5 ). 
2. Update medical history.  
3. A complete physical examination  (at Visit  11 only ). 
4. Body weight, height, and BMI.  
Protocol Amendment #[ADDRESS_994767] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature).  
6. 12-lead ECG after subject has been in supi[INVESTIGATOR_19636] a minimum of 3 minutes  (at 
Visit  11 only ). 
7. Clinical laboratory tests (chemistry, hematology an d urinalysis ) (at Visit 11 only)  under 
fasting conditions . 
8. Perform the C -SSRS  assessment , “Children’s Since Last Visit” version . Subjects with 
clinically significant suicidal ideation, in the opi[INVESTIGATOR_689] , based on the 
C-SSRS assessment , will be exclude d from further participation in the study , and further 
evaluation and/or preventive intervention steps for suicidal behavior will be taken, at the 
discretion of the Investigator.  
9. Urine pregnancy test for a ll female subjects of ch ildbearing potential . See Section 12.[ADDRESS_994768] from further participation in the study.  
10. Perform the ADHD- RS-5 score  assessment.  
11. Perform the clinician -administered CGI -S scale assessment . 
12. Perform the CSHQ.  The Investigator or designee will fill in the CSHQ questionnaire 
based on an interview with the parent/guardian/caregiver . 
13. If needed, perform a KP415 dose adjustments:  based on the CGI -S, interview with the 
parent /guardian/caregiver , and safety data, the I nvestigator will evaluate the subject’s 
therapeutic responses and tolerability to treatment, and decide whether the current 
KP415 dose should be increased, decreased, or remain the same . At a ny day during the 
Treatment Phase, the daily dose will be either 20, 30 or 40 mg KP415  capsules . 
14. Stimulant ADHD medications (with the exception of study drug), including herbal 
medications, are prohibited from 5 days prior to Visit 5 to the end of the Foll ow-Up 
Visit or Early Termination Visit. Non- Stimulant ADHD medications are prohibited 
from 14 days prior to the start of Visit 5 to the end of the Follow -Up Visit or Early 
Termination Visit. Other prohibited medications with their associated time windows 
when they are prohibited are listed in Section 10 . 
15. The appropriate dose of unblinded study drug  (KP415)  to be taken at home once -a-day 
in the morning on each day until the next visit  will be dispensed to the subjects.  
16. Assessment  and review of Adverse Events , and the s ubject’s parent/guardian will be 
Protocol Amendment #[ADDRESS_994769] the study site for the reporting of AEs during the dosing periods at 
home . 
17. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
9.4.4.  Visit 17 (EOT Visit)  
The following procedures will be performed at the End -of-Treatment Visit (EOT, Visit 17) after 
administration of the last dose of study drug:  
1. Record the number of returned and administered capsules of unblinded study drug for 
drug accountability and compliance . 
2. Update medical history.  
3. A complete physical examination.  
4. Body weight, height, and BMI.  
5. Vital signs after a minimum of [ADDRESS_994770] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature).  
6. 12-lead ECG after subject has been in supi[INVESTIGATOR_19636] a minim um of 3 minutes.  
7. Clinical laboratory tests (chemistry, hematology an d urinalysis)  under fasting 
conditions . 
8. Urine pregnancy test for all female subjects of childbearing potential . See Section 12.9  
for the definition of childbearing potential.  
9. Perform the C -SSRS  assessment , “Children’s Since Last Visit” version . If a s ubject has 
clinically significant suicidal ideation, in the opi[INVESTIGATOR_689] , based on the 
C-SSRS assessment , further evaluation and/or preventive intervention steps for suicidal 
behavior will be taken, at the discretion of the Investigator.  
10. Perform the ADHD -RS-5 score assessment.  
11. Perform the clinician -administered CGI -S scale assessment . 
12. Perform the CSHQ.  The Investigator or designee will fill in the CSHQ questionnaire 
based on an interview with the parent/guardian/caregiver . 
13. Stimulant ADHD medications (with the exception of study drug), including herbal 
medications, are prohibited from 5 days prior to Visi t 5 to the end of the Follow -Up 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 68 of 97   May 09, 2019  
 Visit or Early Termination Visit. Non- Stimulant ADHD medications are prohibited 
from 14 days prior to the start of Visit 5 to the end of the Follow -Up Visit or Early 
Termination Visit. Other prohibited medications with their  associated time windows 
when they are prohibited are listed in Section 10 . 
14. Assessment  and review of Advers e Events . 
15. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
9.5. Unscheduled Visits  
At the discretion of the Investigator, subjects may be asked to come to the clinical site for an 
unscheduled visit. Subjects  will need to bring their unused study drug to the visit.  
Unscheduled visits can occur at any time dur ing the Dose Optimization Phas e (new subjects only)  
or the Treatment Phase . Examples of reasons to conduct an unscheduled visit:  
• If subjects experience an Adverse Event during the at -home treatment, they must contact 
[CONTACT_977], and, at the discretion of the Investigator, furthe r in-person medical 
evaluation and review may be performed . 
• If subjects experience symptoms of intolerance during the at -home treatment  with study 
drug or have complaints about increases  in ADHD sympt oms, they must contact [CONTACT_31871], and, at the di scretion of the Investigator, their KP415 dose may be adjusted before the 
next scheduled visit.  
The following procedures will occur at the Unscheduled Visit:  
1. Record the number of administered capsules of unblinded study drug for drug 
accountability and com pliance . For this purpose, subjects will be asked to bring their 
unused medication to the clinical site.  
2. Vital signs after a minimum of [ADDRESS_994771] (respi[INVESTIGATOR_697], pulse rate, blood 
pressure, and oral temperature).  
3. Assessment  and review of Adverse  Events.  
4. Review of concomitant medications, treatment and/or therapi[INVESTIGATOR_014].  
The following procedures will occur at the Unscheduled Visit , each at the discretion of the 
Investigator : 
1. Evaluations for safety, as needed (for example, to evaluate and review Adverse Events):  
Protocol Amendment #[ADDRESS_994772] has been in supi[INVESTIGATOR_19636] a minimum of 3 
minutes  
c. C-SSRS, “Children’s Since Last Visit” version . Subjects with clinically 
significant suicidal ideation/behavior, i n the opi[INVESTIGATOR_689] , based 
on the C -SSRS assessment , will be exclude d from further participation in the 
study , and further evaluation and/or preventive intervention steps for suicidal 
behavior will be taken, at the discretion of the Investigator.  
d. Clinical laboratory  assessments  
2. If, at the discretion of the Investigator, an unscheduled evaluation of the changes in 
ADHD symptoms is needed, for a potential unscheduled dose level change of study  
drug:  
a. If needed, perform an assessment of ADHD severity. This may include an  
ADHD- RS-5 and/or CGI-S scale assessment , and/or , during the Dose 
Optimization Phase (new subjects only), a CGI -I scale assessment.  
b. If needed, perform a KP415 dose adjustment : based on the ADHD severity 
assessment , interview with the parent /guardian/caregi ver, and safety data, the 
Investigator will evaluate the subject’s therapeuti c response  and tolerability to 
treatment, and decide whether the current KP415  dose should be increased, 
decreased, or remain the same . On any day during the study , the daily dose  will 
be either 20, [ADDRESS_994773] will be 
withdrawn , and Early Termination procedures will be completed (see Section 9.6). 
9.6. Early Termination Visit  
Early Termination (ET) from the study is defined as withdrawal during the Dose Optimization 
Phase  (new subjects only)  or Treatment Phase (all subjects) after at least one dose of study drug is 
administered. For subjects who withdraw early from the study, the Investigator should make every 
effort to perform all ET procedures before discharging the subject from the research clinic.  
The follow ing procedures will be performed at ET visits:  
1. If appropriate, r ecord the number of returned and administered capsules of unblinded study 
drug for drug accountability and compliance . 
2. Update medical history.  
3. Complete physical examination.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 70 of 97   May 09, 2019  
 4. Body weight , heigh t, and BMI . 
5. Vital signs (respi[INVESTIGATOR_697], pulse rate, blood pressure, and oral temperature) after subject 
has been sitting for a minimum of [ADDRESS_994774] has been in supi[INVESTIGATOR_19636] a minimum of 3 minutes.  
7. Clinical laboratory te sts (chemistry, hematology an d urinalysis).  
8. Urine pregnancy test for all female subjects of childbearing potential . See Section 12.9  for 
the definition of childbearing potential.  
9. Assessment of the C -SSRS, “Children’s Since Last Visit” version. If a subject has, i n the 
opi[INVESTIGATOR_689], clinically significant suicidal ideation/behavior, based on the C -
SSRS assessment , further evaluation and/or preventive intervention steps for suicidal 
behavior will be taken, at the discretion of the Invest igator.  
10. Stimulant ADHD medications (with the exception of study drug), including herbal 
medications, are prohibited from 5 days prior to Visit 5 to the end of the Follow -Up Visit or 
Early Termination Visit. Non -Stimulant ADHD medications are prohibited fro m 14 days 
prior to the start of Visit 5 to the end of the Follow -Up Visit or Early Termination Visit. 
Other prohibited medications with their associated time windows when they are prohibited 
are listed in Section 10 . 
11. Review of concomitant medications, trea tment and/or therapi[INVESTIGATOR_014].  
12. Assessment  and review  of Adverse E vents.  
At the discretion of the Investigator, ensuring the safety of the subjects, any ET procedures that 
were already performed on the same day as part of the study phase from where the subject ent ers 
ET, do not need to be repeated.  
Subjects will be discharged from the study clinic when the Investigator determines that the subjects 
are medically stable and, if possible, after all ET procedures are completed.  
Subjects who withdraw early from the study and complete the above ET procedures will not return 
for a Follow -Up Visit. Therefore, the ET Visit is the EOS for these subjects.  
9.7. Follow -Up Visit  
Subjects who complete  the Treatment Phase will return in 3 ±[ADDRESS_994775] dos e of study drug for the Follow -Up Visit.  
The following procedures will be completed during the Follow -Up Visit:  
Protocol Amendment #[ADDRESS_994776] (respi[INVESTIGATOR_697], pulse rate, blood pressure, 
and oral temperature).  
4. Urine pregnancy test for all female subjects of childbearing potential . See Section 12.9  for 
the definition of childbearing potential.  
5. Assessment of the C -SSRS, “Children’s Since Last Visit” version . If a subject has, i n the 
opi[INVESTIGATOR_689], clinically significant suicidal ideation/behavior, based on the C -
SSRS assessment , further evaluation and/or preventive intervention steps for suicidal 
behavior will be taken, at the discretion of the Investigator . 
6. Stimulant ADHD medications (with the exception of study drug), including herbal 
medications, are prohibited from 5 days prior to Visit 5 to the end of the Follow -Up Visit or 
Early Termination Visit. Non -Stimulant ADHD medications are prohibited from 14  days 
prior to  the start of Visit 5 to the end of the Follow -Up Visit or Early Termination Visit. 
Other prohibited medications with their associated time windows when they are prohibited 
are listed in Section 10 . 
7. Review of concomitant medications, treatment and/or thera pi[INVESTIGATOR_014]. 
8. Assessment  and review  of adverse events.  
The Follow -Up Visit is the EOS for subjects who will undergo the Follow -Up procedures.  
9.8. End of Study (EOS)  
The End of Study (EOS) is either the Follow -Up Visit for subjects who complete the Treatment 
Phase, or the Early Termination Visit for subjects who  withdraw early from the study.  
10. CONCOMITANT MEDICATIONS AND RESTRICTIONS  
Subjects will adhere to th e following restrictions before  and after administration of study drug , as 
specified : 
10.1. Medication Restrictions for Rolled -Over Subjects  
Rolled -over subjects will be prohibited/limited to receive certain medications in the trial, as follows:  
• Stimulant ADHD medications (with the exception of study drug), including herbal 
medications, are prohibited from 5 days prior to the start of the Treatment Phase (Visit 5) to 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 72 of 97   May 09, 2019  
 the end of the Follow -Up Visit or Early Termination Visit. These include: methylphenidate, 
amphetamine, Ritalin®, Ritalin® SR, Metadate® ER, Concerta®, dextromethylphenidate, 
Focalin®, dextroamphetamine, Dexedrine®, Adderall®. 
• Non-Stimulant ADHD medications are prohibited from 14 days prior to the start of the 
Treatment Phase (Visit 5) to the end of the Follow -Up Visit or Early Termination Visit. 
These include: Atomoxetine, guanfacine, clonidine;  and SSRIs such as fluoxetine and 
paroxetine.  
• The following medications are prohibited from 14 days prior to the start of the Treatment 
Phase (Visit 5) to the end of the Follow -Up Visit or Early Termination Visit: 
o Tricyclic antidepressants.  
o Monoamine oxida se inhibitors (MAOIs).  
o Mood stabilizers (e.g., lithium, valproate, quetiapi[INVESTIGATOR_050]).  
o Antipsychotics (e.g., risperidone, olanzapi[INVESTIGATOR_050]).  
o Coumarin anticoagulants. 
o Anticonvulsants. 
o Halogenated anesthetics.  
o Phenylbutazone  
 
• Sedative hypnotics/sleep enhancers (with the exception of melatonin) are prohibited from 
14 days prior to the start of the Treatment Phase (Visit 5) to the end of the Follow -Up Visit 
or Early Termination Visit.  
• Melatonin is allowed if subjects have taken it for more than 30 days before the start of the 
Treatment Phase (Visit 5) and are on a stable dose. Otherwise, melatonin is prohibited from 
5 days prior to the start of Visit 5 to the end of the Follow -Up Visit or Early Termination 
Visit . 
If subjects participated in a previous study with KP415 (i ncluding Study KP415.E01), they 
are allowed to take any medications (including ADHD medications) after completing the 
previous study with KP415 and before starting the current study, except for the medications 
and the time intervals specified in this proto col. 
10.2. Medication  Restrictions  for New Subjects  
• Stimulant ADHD medications (with the exception of study drug), including herbal 
medications, are prohibited from 5 days prior to the start of the Dose Optimization Phase 
(Visit 2 ) to the end of the Follow -Up Vi sit or Early Termination Visit. These include: 
methylphenidate, amphetamine, Ritalin®, Ritalin® SR, Metadate® ER, Concerta®, 
dextromethylphenidate, Focalin®, dextroamphetamine, Dexedrine®, Adderall®. 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 73 of 97   May 09, 2019  
 • Non-Stimulant ADHD medications are prohibited from 14 days prior to the start of the Dose 
Optimization Phase ( Visit 2 ) to the end of the Follow -Up Visit or Early Termination Visit. 
These include: Atomoxetine, guanfacine, clonidine; and SSRIs such as fluoxetine and 
paroxetine.  
• The following medications are prohibited from 14 days prior to the start of the Dose 
Optimization Phase ( Visit 2 ) to the end of the Follow -Up Visit or Early Termination Visit: 
o Tricyclic antidepressants.  
o Monoa mine oxidase inhibitors (MAOIs)  
o Mood stabilizers  (e.g., lithium, valproate, quetiap ine) 
o Antipsychotics (e.g., risperidone, olanzapi[INVESTIGATOR_050])  
o Coumarin anticoagulants  
o Anticonvulsants  
o Halogenated anesthetics  
o Phenylbutazone  
 
• Sedative hypnotics/sleep enhancers (with the exception of  melatonin) are prohibited from 
14 days prior to the start of the Dose Optimization Phase ( Visit 2 ) to the end of the Follow -
Up Visit or Early Termination Visit.  
• Melatonin is allowed if subjects have taken it for more than 30 days before the start of the 
Dose Optimization Phase ( Visit 2 ) and are on a stable dose. Otherwise, m elatonin is 
prohibited from 5 days prior to Visit 2  to the end of the Follow -Up Visit or Early 
Termination Visit.  
Medications allowed during the course of the study include nasal steroi ds, bronchodilators, 
acetaminophen and nonsteroidal anti -inflammatory medications; non -sedating antihistamines such 
as cetirizine, loratadine, and fexofenadine; mometasone; and approved courses of prescription and 
nonprescription medications for the treatm ent of acute illnesses . 
10.3. Birth Control  
Female subjects must agree, when they are of childbearing potential at Screening or when they 
become of childbearing potential during the study  to use one of the following forms of birth control 
from screening until [ADDRESS_994777] dos e of study drug has been taken, unless a different 
timeframe is listed below:  
a. Double barrier (diaphragm with spermicide; condoms with spermicide)  
b. Intrauterine device (IUD)  
c. Total abstinence (must agree to use a double barrier method if they become sexually 
Protocol Amendment #[ADDRESS_994778] dos e of study drug ). 
d. Implanted or intrauterine hormonal contraceptives in use for at least 3 consecutive 
months prior to Screening.  
e. Oral, patch, or injected contraceptives, or vaginal hormonal device (i.e., NuvaRing®), in 
use for at least [ADDRESS_994779] dos e of study drug has been take n. 
“Of childbearing potential” is defined in Section 12.[ADDRESS_994780]  
11.1. Active Pharmaceutical Ingredients  
The chemical name [CONTACT_4007] t he KP415 prodrug is 3-(((S)- 1-carboxy -2-hydroxyethyl)carbamoyl) -1-
((((R)- 2-((R)-2-methoxy -2-oxo-1-phenylethyl)pi[INVESTIGATOR_728282]-1-carbonyl)oxy)methyl) pyridine -1-ium 
chloride. It is a single d -methylphenidate molecule covalently attached via a carbamate bond to a 
methylene oxide linker which in turn is connected to the nitrogen of the pyridine ring of a 
nicotinoyl -serine moiety.  
11.2. Clinical Trial Material  
The capsules of study drug (KP415 capsules) with contain two active pharmaceutical ingredients: 
d-methylphenidate hydrochloride as the immediate release  (IR) d-methylphenidate component, and 
KP415 prodrug as the extended release  (ER) d-methylphenidate component. In terms of d- MPH  
equivalent amounts , all capsule st rength s contain 30% of d- MPH (IR component) and 70% of d-
MPH from the KP415 prodrug.  The total equivalent amount of d- methylphenidate (d -MPH) in each 
capsule strength (used as daily doses in this study), and the amounts of both APIs are listed in the 
following table.  
Total  
d-MPH 
dose  1 
(mg)  d-MPH  2 
 
 
(mg)  KP415  
Prodrug 3 
 
(mg)  
20 6 28 (14) 
30 9 42 (21)  
40 12 56 (28)  
1. Based on the d -MPH amount plus the equivalent amount of d -MPH as KP415 prodrug.  
2. The dose of d- MPH is expressed in terms of d -methylphenidate hydrochloride . 
3. The dose of KP415 prodrug is expressed in terms of KP415 chloride . The amount of d-MPH  hydrochloride  
equimolar to each KP415 prodrug dose  is liste d between parentheses.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 75 of 97   May 09, 2019  
  
The KP415 prodrug is not yet a scheduled  controlled substance ; however, methylphenidate is a 
Schedule II substance under the Controlled Substances Act. As a result of the d- MPH content in the 
KP415 capsules, the drug product used in this study is a Schedule II product. Therefore, study sites 
are required to have the appropriate permit from the Drug Enforcement Agency (DEA) to receive, 
store, ship and dispense the KP415 product according to all local, state, and federal regulat ions for 
Schedule II substances.  
Unblinded capsules with 20, [ADDRESS_994781]  will be used in the  study . All study drug 
will be supplied by [CONTACT_1034] (or design ee). The Sponsor (or designee) will supply sufficient 
quantities of KP415 to allow for completion of the study. The study drug shipment(s) will be 
shipped to each site after site activation (i.e., after all required regulatory documentation has been 
received by [CONTACT_728305] a contract has been executed).  The lot numbers of  study 
drug supplied will be recorded in the study report.  
All other drug products needed for the conduct of the study (such as allowed medications to treat 
Adverse Events, including acetaminophen and nonsteroidal anti -inflammatory medications ) will be 
commercially available products obtained by [CONTACT_728306].  
11.3. Pharmaceutical Formulation  
KP415 will be  provided in size 3 capsules consisting of a color -coded (by [CONTACT_353162])  hydroxy propyl 
methylcellul ose (HPMC) capsule shell with  text indicating the name (KP 415) and the strength  
(either 20 mg, 30 mg or 40 mg) . Besides KP415 drug substance, e ach capsule of study drug contains 
the following inactive ingredients: microcrystalline cellulose, crospovidone, colloidal silicon 
dioxide, and magnesium stearate.  
11.4. Packagi ng and  Labeling  
The KP415 capsules will be packaged and labeled appropriately , according to the appropriate FDA 
regulations . 
11.4.1.  Dose Optimization Phase  
Unblinded KP415 capsules will be dispensed to the subjects  as bottle s with [ADDRESS_994782] 7 days of dosing in the Dose Optimization  
Phase ( 1 capsule/day) and 3 extra capsule s to cover the potential loss of capsule s or extra dosing 
days before the next visit . Each bottle  will be dispensed with instructions on how to administer 
study drug.  
Protocol Amendment #[ADDRESS_994783] 30  days of dosing in the Treatm ent Phase 
(1 capsule/day) and 5  extra capsule s to cover the potential loss of capsule s or extra dosing days 
before the next visit . Each bottle  will be dispensed with instructions on how to administer study 
drug.  
11.5. Dispensing and Drug Return Procedures  
11.5.1.  Genera l Dispensing and Drug Return Procedures  
Unblinded bottles of drug supply (KP415 capsules) will be dispensed at each visit of the study with 
enough capsules for treatment until the next visit. The assigned study drug will consist of one of the 
following: 20, [ADDRESS_994784]’s parent or guardian with instructions when 
and how to administer study drug while at home, under supervi sion of parent or legal guardian. At 
the day of each visit, subjects may take their dose of study drug at home before coming to the study 
site or subjects will be administered study drug at the study site . Subjects will be instructed to take 
study drug eve ry morning while at home under the supervis ion of their parent/legal 
guardian/caregiver . The capsule needs to be swallowed whole,  or may be taken by [CONTACT_728307] a small amount of applesauce, or putting the content s in a small amount 
of water . See Appendix A  for detailed instructions . 
At each visit, subjects will return to the study site with unused study drug , and site personnel will 
record the number of returned and administered c apsules of unblinded study drug for drug 
accountability and compliance.  
In the event that subjects report lost study drug during the at -home dosing period s, they will be 
instructed to contact [CONTACT_728308] a s possible after the loss. Lost drug supply may be 
replaced with the appropriate new bottle.  
The Investigator will not supply study drug to anyone other than those named as sub- investigators 
on FDA Form 1572, designated site staff, and subjects in the study.  
11.5.2.  Dispensing in Dose Optimization Phase  (Visit 2, 3, and 4)  
Unblinded bottles of drug supply will be dispensed at each visit as follows:  
• Visit 2:  Subjects will be dispensed an unblinded bottle with [ADDRESS_994785]  (starting dose  for Dose Optimization ). 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 77 of 97   May 09, 2019  
 • Visit 3: Subjects will return to the research clinic after 7 ±3 days for Visit 3 with unused 
study drug, and will be dispensed either a bottle with 30 mg KP415  capsules  (same daily 
dose as Week 1), with 20 mg KP415 capsules  (dose l evel decrease from Week 1), or with 
40 mg KP415 capsules  (dose level increase from Week 1).  
• Visit 4:  Subjects will return to the research clinic after 7 ±3 days for Visit 4 with unused 
study drug, and will be dispensed either a bottle with 20, 30 or 40 mg KP415 capsules (same 
daily dose as Week 2, or either a dose level decrease or increase from Week 2 ). 
11.5.3.  Dispensing in Treatment Phase (Visit s 5 to 16) 
Unblinded bottles of drug supply will be dispensed at each visit as follows:  
• Visit 5: Subjects will be dispe nsed an unblinded bottle with 35 capsules of the optimized 
dose of KP415 (either 20 mg, 30 mg or 40 mg capsules). For rolled- over subjects from Study 
KP415.E01, the optimized dose as determined in Study KP415.E01 will be used. For new 
subjects, the optimiz ed dose will be determined at the end of the Dose Optimization Phase 
in the current study.  
• Visit 6 to Visit 16: Subjects will return to the research clinic with unused study drug, and 
will be dispensed a new bottle with [ADDRESS_994786] . Since the Investigator may increase or  decrease the dose of KP415 during the 
Treatment Phase , based on individual tolerability and dose response, the capsule strengths 
dispensed at Visit 6 to  Visit 16  may be different from the previous visit.  
11.5.4.  Dispensing at Unscheduled Visits  
At unscheduled visits (see Section 9. 5), if needed, the I nvestigator may decide to change the daily 
KP415 dose. In this case, a new bottle with capsules of either [ADDRESS_994787]  
will be dispensed to the subjects , and unused study drug previously dispensed will need to be 
returned . The same dispensing and drug return procedures (see Section 11.5.1 ) will be followed as 
for scheduled visits.  
11.6. Storage of Study Drug  
Study drug will be stored at controlled room temperature 20°- 25°C (68° -77°F) with excursions 
allowed between 15° and 30°C (59° and 86°F). Transient spi[INVESTIGATOR_201164] 40°C are permitted as long 
as they do not last for more than [ADDRESS_994788] not be frozen. The Investigator will ensure 
that adequate preca utions are taken, including storage of the study drug in a securely locked, 
substantially constructed cabinet, or other securely locked, substantially constructed enclosure, 
access to which is limited, to prevent theft or diversion of the substance into il legal channels of 
Protocol Amendment #[ADDRESS_994789](s) must be stored as indicated. Deviations from the storage 
requirements, including any actions taken, must be documented and reported to the Sponsor . Once 
a deviation is identified, the investiga tional product must be quarantined and not used until the 
Sponsor provides documentation of permission to use the investigational product.  
11.7. Study Drug Accountability  
An accurate and current accounting of the dispensing and return of study drug  for each subj ect, in 
both the Dose Optimization Phase and the Treatment Phase,  will be maintained on an ongoing basis 
by a member of the study site staff. The number of study drug dispensed will be recorded on the 
Investigational Drug Accountability Record. The study m onitor will verify these documents 
throughout the course of the study. 
12. SAFET Y AND EFFICACY ASSESS MENT S 
12.1. Medical History  
A complete medical history will be obtained at the Screening Visit includ ing the recording of 
demographic data ( date of birth, sex, age, race, ethnicity ), collection of previous surgeries, 
medications and chronic conditions, past or present illnesses or dysfunctions, substance/drug abuse, 
and history of allergies or idiosyncratic responses to drugs. Medical history (changes from 
screening) will be updated at subsequent visits after the Screening Period.  
12.2. Physical Examination  
For all subjects, a  complete physical examination will be completed at Screening, after 
approximately 6 months of treatment (Visit 11), after the las t dose of study drug (Visit 17, EOT), 
and at Ear ly Termination  (if possible) . The complete physical examination will include a review of 
the subject’s general appearance, skin, head and neck (eyes, ears, nose, mouth, and throat), lymph 
nodes, thyroid, musc uloskeletal/ extremities, cardiovascular system, lungs, abdomen and a brief 
examination of the neurological system.  
Body weight, height and BMI will be determined at all visits to follow the growth of the subjects. 
Height will be recorded in centimeters (cm ) with the subject’s shoes removed. Body weight will be 
measured in kilograms (kg) ; subjects will remain in their normal clothing with shoes and jacket 
(and/or outer clothing) removed.  
12.3. ADHD  Diagnosis  and Severity Assessments  
For new subjects a t Screening, eligible subjects must meet the inclusion criteria for a primary 
diagnosis of ADHD  by [CONTACT_170501] -  Fifth Edition 
(DSM -5) criteria for a primary diagnosis of ADHD (combined, inattentive, or 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 79 of 97   May 09, 2019  
 hyperactive /impulsive presentation) per clinical evaluation and confirmed by [CONTACT_728309] (MINI -KID).  
Since r olled -over subjects from Study KP415.E01 will need to have that study completed, their 
ADHD diagnosis and diagnosis confirmation was conducted in Study KP415.E01.  
For all subjects, t he following scales will be used during the study  to globally assess the changes in 
ADHD severity over time : 
• ADHD- Rating Scale -5 (ADHD- RS-5): The ADHD -RS-5 is an 18- item scale (DuPaul 
2016) based on Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM -
5) (American Psychiatric Association 2013) criteria of ADHD that rates symptoms on a 4 -
point scale. Each item is scored using a combination of severity  and frequency ratings 
from a range of 0 (reflecting no symptoms or a frequency of never or rarely) to 3 
(reflecting severe symptoms or a frequency of very often), so that the total ADHD -RS-5 
scores range from 0 to 54. The 18 items can be divided into two 9 -item subscales: One for 
hyperactivity/impulsivity and the other for inattentiveness. Scores will be obtained during 
a clinician -directed interview with the parent/guardian/ caregiver  at each visit  in the Dose 
Optimization Phase . 
• Clinical Global Impression s–Severity (CGI -S): The CGI -S is a clinician -rated scale that 
evaluates the severity of psychopathology (ADHD symptoms in the study) on a scale from 
1 (not at all ill) to 7 (among the most severely ill) (Busner and Targum 2007).  
• Clinical Global Impressions –Improvement (CGI -I): The CGI -I is a clinician -rated scale 
that evaluates the improvement  of psychopathology (ADHD symptoms in the study) on a 
scale from 1 (very much improved) to 7 (very much worse).  
During the  Dose Optimization Phase (new subjects only), the ADHD- RS-5, CGI -I and CGI -S scale 
assessments are the main efficacy  variables (in conjunction with tolerability and safety) to guide 
dose optimization. During the Treatment Phase, the ADHD- RS-5 and CGI -S scale assessments are 
the efficacy  variables to evaluate the changes in ADHD severity over time, and may be used (in 
conjunction with tolerability and safety) to adjust the dose of study drug. 
12.4. Children’s Sleep Habits Questionnaire (CSHQ)  
The modified, abbreviated Children’s Sleep Habits Questionnaire (CSHQ) will be used to assess 
the sleep behavior  during the Treatment Phase . The CSHQ is a retrospective, 33 -item parent 
questionnaire to examine sleep behavior in small children (Owens 2000a, Owens 2000b). Items are 
rated on a 3 -point scale of “Usually”, “Sometimes” and “Rarely” for occurrences in a number of 
key sleep domains. Scores will be obtained during a clinician- directed interview with the 
parent/guardian/caregiver at the visits in the Dose Optimization Phase for new subjects (Visit 2 ) 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 80 of 97   May 09, 2019  
 and in the Treatment Phase for all subjects (Visit 5  to Visit 17 ). 
12.5. Columbia -Suicide Severity Rating Scale (C -SSRS)  
Suicidal ideation will be assessed by  [CONTACT_48649] -Suicide Severity Rating Scale (C -SSRS, 
Pediatric Version)  (Posner  2010) . The “Children’s  Baseline/Screening” version will be assessed at 
Screening, and the “Children’s Since Last Visit” version will be assessed at all visits of the Dose 
Optimization Phase ( new subjects only ), at all of the Treatment Phase  visits , and at Follow -Up or 
Early Ter mination . 
Subjects who, i n the opi[INVESTIGATOR_689], have  clinically significant suicidal 
ideation/behavior, based on history of attempted suicide and the C -SSRS assessment at Screening 
or at any time before the last dose of study drug , will be exclude d from further participation in the 
study , and further evaluation and/or preventive intervention steps for suicidal behavior will be 
taken, at the discretion of the Investigator.  
12.6. Vital Signs  
Vital sign measurements will be obtained after the subject has been seated for 3 minutes. Vital signs 
will include sitting blood pressure (systolic and diastolic measurements), pulse  rate (beats per 
minute), respi[INVESTIGATOR_697] (breaths per minute), and oral temperature . Vital signs will be collected 
once at each vi sit. At the discretion of the Investigator , in order to ensure accuracy, out -of-range 
vital signs may be repeated once, at least [ADDRESS_994790] has been in a s upi[INVESTIGATOR_19636] a minimum of 3 
minutes.  Abnormal ECGs may be repeated for confirmation in which case only the repeated ECG 
will be recorded.  The QT interval  corrected for heart  rate will be calculated with Fridericia’s 
formula (QTcF).  ECGs will be obtained at Screening , after approximately 6 months of treatment 
(Visit 11), after the last dose of study drug (Visit 17, EOT), and at Ear ly Termination (if possible) . 
ECG recordings will be evaluated by [CONTACT_728310] a centralized ECG laboratory.  
12.8. Clinical Laboratory Measurements  
All clinical laboratory samples will be sent to a central laboratory for analysis. Up to approximately 
[ADDRESS_994791] (if 
applicable) fr om each subject during the study. Clinical Laboratory Measurements will be 
performed at Screening, after approximately 6 months of treatment (Visit 11), after the last dose of 
study drug (Visit 17, EOT), and at Early Termination (if possible). Samples for Clinical Laboratory 
Measurements at Screening Visit 1A (new subjects), Visit 11, and Visit 17 (EOT) will be collected 
under fasting conditions.  
Protocol Amendment #[ADDRESS_994792] of the following:  
• Total Hematology as well as differential and Coagulation: red blood cell count, white 
blood cell count with differential (neutrophils, lymphocytes, monocytes, eosinophils, 
basophils), hemoglob in, hematocrit and platelets,  Prothrombin Time (PT) and  Partial 
Thromboplastin Time (PTT).  
• Serum Chemistry: aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
albumin, alkaline phosphatase, bicarbonate, total bilirubin, blood urea nitrogen, 
phosphorus (inorganic) calcium, chloride, creatine phosphokinase, creatinine, gamma 
glutamyl tran sferase, glucose, lactate dehydrogenase, potassium, sodium, total protein, 
thyroid stimulating hormone (TSH ), and uric acid.  TSH will be measured at Screening 
only, for New Subjects only  who did not previously participated in Study KP415.E01 (to 
evaluate t he exclusion criterion for uncontrolled thyroid disease) . 
• Urinalysis: microanalysis for specific gravity, pH, protein, glucose, ketones, blood, 
nitrites, leukocytes. If positive  for blood, protein or nitrites , a microscopic examination 
will be performed.  
• Urine Screen for Alcohol Drugs of Abuse  (new subject s only) : At Screening (Visit 1), 
urine samples will be tested for alcohol  and drugs of abuse (amphetamines, 
methamphetamines, benzodiazepi[INVESTIGATOR_1651], barbiturates, cannabinoids, cocaine, opi[INVESTIGATOR_728283]) . If the urine test is positive for alcohol  and drugs of abuse  at 
Screening, the subject will be excluded from study participation, with the exception of the 
following: Depending on a subject's current ADHD medication at Screening, the urine 
screen at Screening may test positive for ADHD medications such as amp hetamines  and 
methamphetamines . 
• Urine Screen for Methylphenidate: At Screening (Visit 1 A, new subjects only ), Visit 2 
(new subjects only) and Visit 5 (roll -over subjects only) , urine samples will be tested for 
methylphenidate . A urine dipstick (e.g., NarcoCheck®) will be used to screen for the 
presence of methylphenidate in the urine . If a subject's current ADHD medication at 
Screening (Visit 1A , new subjects) contains MPH, the urin e screen at Screening may test 
positive for MPH.  
12.9. Pregnancy Test  
Pregnancy Tests will be performed for all female subjects of childbearing potential. A serum β -
hCG pregnancy test will be performed at Screening. A urine pregnancy test will be performed at 
Visits 2 (new subjects), at Visit  [ADDRESS_994793]. 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 82 of 97   May 09, 2019  
 Childbearing potential is defined as follows: Girls under the age of [ADDRESS_994794] 
period will be considered “not of child- bearing potential”. Girls of 12 years and older (including 
girls who will b ecome 12 years or older during the study) will be considered “of child- bearing 
potential”, even if they have not yet had their first period. Irrespective of age, girls who have had 
their first period, will be considered “of child -bearing potential”.  
12.10.  Advers e Event Assessments  
Adverse Events will be assessed and recorded from the first day of study drug administration  
through either Follow -Up or Early Termination. While subjects are at the research clinic after 
administration of study drug , AEs will be monitored continuously  by [CONTACT_464] . During 
administration of study drug away from the research clinic, s ubject’s parent/guardian will be 
instructed to contact [CONTACT_728311] . In 
addition, study staff will inquire parent/guardian during the next study visit about AEs during the 
dosing period at home . Definitions and details of AE reporting and documentation are listed in 
Section  16. In cases in which  the occurrence of an AE  to the subject is unclear  or for safety -related 
medical questions , the Medical Monitor should be consulted  (for contact [CONTACT_3031], see Page 2) . 
13. DISCONTINUATION AND REPLACEMENT OF SUBJECTS  
13.1. Withdrawal of Subjects from the Study  
A subject may be discontinued or choose to withdraw from study treatment at any time if the subject, 
the Investigator, or the Sponsor feels that it is not in the subject’s best interest to continue. The 
following is a list of possible reasons for study treatment discontinuation:  
• Subject withdrawal of consent . 
• Subject is not compliant with study procedures.  
• Adverse event that in the opi[INVESTIGATOR_728284] . 
• Lack of efficacy  
• Protocol violation requiring discontinuation of study treatment . 
• Lost to follow -up when there is no response to two attempts by [CONTACT_17084] a registered 
letter to the subject. After these [ADDRESS_994795] to 
follow -up. 
• Sponsor request for early termination of the study . 
• Positive pregnancy test ( tested in females  of childbearing potential)  before the last dose 
of study drug . 
• Out-of-range v ital signs , at the discretion of the Investigator. I n order to ensure accuracy, 
out-of-range vital signs may be repeated once, at least 2 minutes  after an abnormal 
finding.  
• For other reasons (e.g., significant protocol violation, non- compliance, overdose).  
 
If a subject is withdrawn from treatment due to an adverse event, the subject will be followed and 
Protocol Amendment #[ADDRESS_994796] 6  months of daily 
oral doses of KP415 capsules. Therefore, the primary endpoint is the safety. 
14.1. Safety Endpoints  
• The occurrence of Treatment -Emergent Adverse Events (TEAE s) will be assessed starting 
following the first dose of study drug, and ending with the Follow -Up Visit or Early 
Termination Visit.  
• Physical examinations will be performed at the first visit ( at Screening, before the first dose 
of study drug), after appro ximately 6 months of treatment (Visit 11), and at the end of the 
Treatment Phase (Visit 17 , EOT ) or at Early Termination.  
• Clinical laboratory tests will be performed at the first visit ( at Screening, before the first 
dose of study drug), after approximatel y 6 months of treatment (Visit 11), and at the end of 
the Treatment Phase (Visit 17 , EOT ) or at Early Termination . 
• ECG parameters will be collected at the first visit ( at Screening, before the first dose of 
study drug), after approximately 6 months of trea tment (Visit 11), and at the end of the 
Treatment Phase (Visit 17 , EOT ) or at Early Termination . 
• Vital signs, height, weight, and BMI will be collected at each visit.  
• A C-SSRS will be performed at each study visit.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 84 of 97   May 09, 2019  
 14.2. Efficacy  Endpoints  
During the Dose Optimization Phase (new subjects only):  
• CGI-S will be assessed at each visit (Screening to Visit 5).  ADHD- RS-5 will be 
administered at Visits 2 through Visit 5. CGI -I will be assessed at Visits 3, 4, and 5 
(since CGI -I is an AD HD improvement assessment , it will not be assessed at Screening  
and at Visit 2 ). 
During the Treatment Phase (all subjects) : 
• ADHD- RS-5 and CGI -S will be assessed at each visit (Visit 5 to Visit 17, EOT).  
14.3. Sleep Behavior Endpoint  
The modified, abbreviated Children’s Sleep Habits Questionnaire (CSHQ) will be used to ass ess 
the sleep behavior in the Dose Optimization Phase for new subjects (Visit 2) and in the Treatment 
Phase for all subjects (Visit 5 to Visit 17) . The baseline will be measured before the first dose of 
study drug, a t Visit 2 for new subjects  and at Visit 5 for roll- over subjects . 
15. STATISTICAL CONSIDERATIONS  
This section summarizes the statistical considerations for this protocol. Details will be provided in 
the Statistical Analysis Plan (SAP ) prior to the primary endpoint database lock of the trial.  
15.1. Sample Size Calculation  
No formal sample size calculations w ere conducted. It was determined that approximately [ADDRESS_994797]  6 months.  Assuming a 
maximum  dropout rate of 20% over 6 months, approximately 250 subjects will  be enrolled.  
15.2. Populations for Analysis  
Data will be analyzed in this study  in the following  analysis populations : 
• Treatment -Phase Safety Population: All enrolled  subjects in the Treatment Phase who 
received at least one dose of study medication in the Treatment Phase and had at least one post -
dose safety assessment  in the Treatment Phase . 
• Efficacy Population:  All enrolled  subjects who received at least [ADDRESS_994798] the efficacy parameters . 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 85 of 97   May 09, 2019  
 • Dose -Optimization Safety Population:  All enrolled  subjects in the Dose Optimization Phase 
(“New Subjects ”) who received at least one dose of study medication  in the Dose Optimization 
Phase  and had at least one post -dose safety assessment  in the Dose Optimization Phase.  
15.3. Statistical Analyses  
15.3.1.  General Approach  
The primary  focus of the statistical analyses are the safety assessment s during the Treatment Phase. 
The secondary focus of the statistical analyses is  the efficacy  during the Treatment Phase. The safety 
and efficacy  parameters during the Dose Optimization Phase (for new subjects only) will be 
summarized descriptively. The efficacy results will be judged with caution since this study is open 
label and has no control group.  
Analysis Populations : All baseline analys es will be performed using the Treatment -Phase Safety 
Population. The primary safety  analys is (during the Treatment Phase) will be performed using the 
Treatment -Phase Safety Population.  The efficacy  analyses and sleep behavior (CSHQ) across the 
Treatment Phase  will use the Efficacy  Population.  Data from the Dose Optimization Phase ( Dose -
Optimization Safety Population ) will be summarized descriptively.  
Descriptive Statistics:  For descriptive statistics, the following will be reported:  
• Continuous data: n, mean, s tandard deviation, coefficient of variation (CV %), median , 
minimum and maximum.  
• Categorical  data: n/N, percentage of total per arm and 95% confidence interval per 
category . 
 
15.3.2.  Attrition  
The number of subjects enrolled and the number of subjects remaining in the study by [CONTACT_728312]. The number of subjects who withdraw early from the study will be tabulated with the 
reason for early withdrawal. The main reasons overall for early withdrawal will be determined.  For 
each main reason for early withdrawal, an assessment will be made when in the course of treatment 
most subjects withdrew early. Baseline variables and dose of study drug will be compared between 
subjects who withdrew early and subjects who completed the s tudy.  
15.3.3.  Drug Exposure and Dosing Pattern  
The mean daily dose of KP415 (mg), the mean daily dose of KP415 by [CONTACT_18694] (mg/kg), and 
the mean daily dose of KP415 by [CONTACT_51737] (mg/m2) will be calculated by [CONTACT_24473], and will 
be compared over time (percent change from starting dose in the Treatment Phase) to explore dose 
changes over the course of the study . The number of subjects who did not take study drug for any 
continuous period of ≥7,  ≥14, ≥21, and ≥28 days in the Treatment Phase will be counted and 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 86 of 97   May 09, 2019  
 reported.  
15.3.4.  Primary Endpoint Analysis  (Safety in the Treatment Phase)  
The primary  safety analysis will be conducted on the Treatment -Phase Safety Population . The 
safety assessment will be bas ed on adverse events, physical exam inations , vital signs, height , 
weight , and BMI, ECG parameters , clinical laboratory tests  and C -SSRS scores . The baseline for 
the safety parameters will be measured at Visit 1A and 1B.  
Adverse events will be coded in accordance with the Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events with new onset during the study between the initiation of  study drug 
and [ADDRESS_994799] dose of study drug will be considered treatment -emergent (TEAEs). This 
will include any AE with onset prior to initiation of study drug and increased severity after the 
treatment initiation.  
TEAEs  will be summarized by  [CONTACT_6657], overall and by [CONTACT_728313] . 
This will include overall incidence rates (regardless of severity and relationship to study drug) and 
incidence rates for moderate or severe adverse events. A summary of serious adverse e vents and 
adverse events leading to early discontinuation from the study will be summarized by [CONTACT_728313] . 
Safety laboratory tests and vital signs will be summarized by [CONTACT_447] -treatment change from baseline 
for each of the parameters using descriptive stat istics overall and by [CONTACT_728313]. Those subjects 
with significant laboratory abnormalities will be identified in data listings. Additional safety 
parameters will be summarized in data listings.  See Section 1 6 for more information on safety data.  
15.3.5.  Secondar y Endpoint Analyses ( Efficacy and CSHQ  in the Treatment Phase)  
Changes in ADHD -RS-5, CGI -S and CSHQ will be analyzed in the Efficacy  Population. The 
baseline for ADHD -RS-5, CGI-S and CSHQ will be measured at Visit 5  for roll -over subjects and 
at Visit 2 for new subjects . 
15.3.6.  Descriptive  Analys es (Safety and Efficacy  in the Dose Optimization Phase)  
For new subjects only, the safety and efficacy parameters during the Dose Optimization Phase 
(Dose -Optimization Safety Population , from Screening to Visit 5) will be summarized 
descriptively. The baseline will be measured at Screening or at Visit 2 (before the first dose in the 
Dose Optimization Phase).  
15.3.7.  Abuse Potential Safety Analyses  
In accordance with the 2017 FDA Guidance for Industry, Assessment of Abuse Potenti al of Drugs, 
the following analyses will be performed in the Treatment Phase : 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 87 of 97   May 09, 2019  
 • Systematic categorization and tabulation of AEs that are abuse potential -related , using the 
MedDRA Preferred Terms , including euphoria -related terms , terms  of altered attention, 
cognition and mood , and  dissociative/psychotic  terms  (FDA Guidance 2017, Sellers and 
Romach  2017) . An analysis by [CONTACT_2715] , age, and gender;  and by [CONTACT_23353], in order to understand 
the incident that led to the AEs, establish the time at which AEs appear following drug 
administration, the duration of the AEs, and which AEs overlap temporally . 
• Analysis of subject’s study drug accountability assessments that may provide information 
about the incidence of signals suggestive of abuse, such as substance use disorders, 
overdose, drug diversion or drug loss.  
15.3.8.  Baseline Descriptive Statistics  
The key baseline characteristics (see the Statistical Analysis Plan (SAP) for list of baseline 
characteristics) will summarized descriptively . 
15.3.9.  Planned Interim Analys is 
An interim analysis of the safety data will be conducted after approximately all subjects remaining 
in the study have completed 180 days  (approximately 6 months) of treatment  (Visit 11 ). The focus 
of the interim analys is are  the safety assessment s (primary  endpoints, See Section 15.3.5 ) during 
the first 6 months of tre atment  in the Treatment Phase . The safety data will be analyzed with the 
same statistical methods as planned for the main analysis after completion of the study. The results 
from the interim s afety analysis will be used to determine whether the study can be stopped (see 
Section 8.6  for the stoppi[INVESTIGATOR_004] ). All other endpoints (including the secondary endpoints ) and 
assessments will also be analyzed as part of the interim analysis.  
15.3.10.  Subg roup Anal yses 
Subgroup analyses will include safety , efficacy  and CSHQ endpoints by [CONTACT_3885], dose (including 
cumulative dose), duration of treatment, previous stimulant exposure , age, gender , and race . 
Subgroup analyses will focus on the Treatment Phase.  Subgrou p analyses will be described in the 
SAP.  
15.3.11.  Tabulation of Individual Participant Data 
All data will be listed. L istings will be sorted in the following order : treatment, subject ID, parameter 
(where applicable), and visit (where applicable) . For TEAEs, a  listing with date and type of each 
subject ’s TEAE  will be provided.  Details will be outlined in the SAP.  
15.3.12.  Exploratory Analyses  
Exploratory analyses will be desc ribed in the SAP.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 88 of 97   May 09, 2019  
 16. ADVERSE EXPERIENCE REPORTING AND DOCUMENTATIO N 
16.1. Adverse Events  
16.1.1.  Recording and Monitoring of Adverse Events  
For the purpose of this clinical trial, all A dverse Events will be recorded and monitored for all 
enrolled subjects from the moment they receive the dose of study drug  until they complete the study 
at the EOS (the F ollow -Up visit  or the Early Termination Visit) . 
16.1.2.  Definition  
An adverse event (AE) is any untoward medical occurrence in a clinical investigation of a patient 
administered a ph armaceutical product and that does not necessarily have a causal relationship with 
the treatment. An AE is therefore any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom or disease temporally associated with the administr ation of an 
investigational product, whether or not related to that investigational product. An unexpected AE is 
one of a type not identified in nature, severity, or frequency in the current Investigator’s Brochure 
or of greater severity or frequency than expected based on the information in the Investigator’s 
Brochure.  
The Investigator will probe, via discussion with the subject, for the occurrence of AEs during each 
subject visit and record the information in the site’s source documents. Adverse events wi ll be 
recorded in the patient eCRF. Adverse events will be described by [CONTACT_24109] (start and stop dates and 
times), severity, outcome, treatment and relation to study drug, or if unrelated, the cause.  
16.1.3.  AE Grading   
Adverse Events shall be graded with regard t o severity according to criteria defined in the Common 
Terminology Criteria fo r Adverse Events v4.0 (CTCAE). Grade refers to the severity of the AE. 
The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE 
based on this general guideline.  
Grade 1  Mild ; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental Activity of Daily Living (ADL) . 
Grade 3  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting 
self-care ADL.  
Grade 4  Life-threatening consequences; urgent intervention indicated.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 89 of 97   May 09, 2019  
 Grade 5  Death related to AE.  
16.1.4.  AE Relationship to Study Drug  
The relationship of an AE to the study drug should be assessed using the following : 
1. Definitely - Previously known toxicity of agent; or an event that follows a rea sonable 
temporal sequence from administration of the drug; that follows a known or expected 
response pattern to the suspected drug; that is confirmed by [CONTACT_13635][INVESTIGATOR_528026]; and that is not explained by [CONTACT_728314]. 
2. Probably - An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to the suspected drug; that is 
confirmed by [CONTACT_13635][INVESTIGATOR_11125]; and that is unli kely to be 
explained by [CONTACT_20612]’s clinical state or by [CONTACT_41847].  
3. Possibly - An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to that suspected drug; but that 
could readily have been produced by a number of other factors.  
4. Unrelated - An event that can be determined with certainty to have no relationship to the 
study drug.  
16.2. Serious A dverse Events 
A Serious Adverse Event ( SAE ) is defined as any AE occurring at any dose that results in any of 
the following  outcomes:  
• Death 
• A life-threatening adverse experience  
• Inpatient hospi[INVESTIGATOR_1081]  
• A persistent or significant disability/incapacity  
• A congenital anomaly/birth defect  
• Other important medical events may also be considered an SAE when, based on 
appropriate medical judgment, they jeopardize the subject or require intervention 
to prevent one of the outcomes listed. 
 
Note that AEs of Grade 3 due to hospi[INVESTIGATOR_17127] a hospi[INVESTIGATOR_059], and Grade 4 
and Grade 5 per CTCAE grading criteria are classified as SAEs.  
16.2.1.  Serious Adverse Event Reporting  
Within 24 hours after a SAE detection, observation, or report of occurrence (regardless of the 
Protocol Amendment #[ADDRESS_994800] article) , the investigator/qualified designee will complete a paper 
SAE /Overdosage  report form with required information regarding the SAE and submit the 
completed  form to Premier Research  Pharmacovigilance . The data will also be entered into the 
appropriate module of the EDC  as soon as possible after the paper  form is sent to Premier Research 
Pharmacovigilance.  
The site is to report SAEs in the EDC and at the same time report via SAE report paper form to 
the below contact [CONTACT_2997]:  
 
Premier Research Pharmacovigilance email address:  
GlobalPV -US@premier -research.com  
Fax Number: 215- 972-[ADDRESS_994801] co ntain the following information:  
1. Study name/number  
2. Study Drug  
3. Investigator details (name, phone, fax, e -mail)  
4. Subject Number  
5. Subject Demographics  
6. Clinical Event 
7. Description  
a. Date of onset  
b. Treatment (drug, dose, dosage form)  
c. AE Relationship to study drug 
d. Action taken regarding study drug in direct relationship to the 
AE 
e. Criteria for “Serious” applicable to the AE  
8. Cause of death (whether or not the death was related to study drug)  
9. Autopsy findings (if available)  
 
Any SAE that occurs during the study  should be recorded by [CONTACT_728315], and reported to the 
Sponsor or designee.  
SAEs considered definitely, probably, or possibly related to study drug shall also be classified by 
[CONTACT_728316] “expected” or “unexpected.” An unexpected event is one that is not listed in the 
investigator’s brochure (KP415) . 
The person responsible for the study shall ensure the study has been carried out in accordance with 
local pharmacovigilance regulations.  
All serious event s reporting by [CONTACT_355795] 21 CF R 312.32 for IND drugs (7 -day or 15-
day alerts) . Unexpected fatal or life- threatening SAEs considered related to the study drug should 
be reported to the FDA by [CONTACT_728317] D Safety report within [ADDRESS_994802] (IRB) will be n otified of the alert reports per FDA regulations.  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 91 of 97   May 09, 2019  
 16.3. Adverse Event Treatment and Follow -Up 
All AEs, including SAEs, will be followed to resolution when possible. All AEs and treatment 
administered will be recorded on the electronic C ase Report Form ( eCRF).  Treatment may be 
rendered on site under the direction of the Investigator as appropriate. Events requiring diagnostic 
evaluation or treatment beyond the scope of what is available and appropriate within the clinical 
research unit shall be referred in a timel y basis to other care providers. Records of diagnostic and 
therapeutic interventions shall be requested in compliance with HIPAA requirements, and those 
received shall be retained in the subject’s file.  
For SAEs that occur during the study, the assessment, treatment, and follow up shall be performed 
for up to at least [ADDRESS_994803] dose  used in the study, i.e., 
>[ADDRESS_994804] . Within 24 hours after overdosage detection t he Investigator or designee 
will complete a paper SAE/Overdosage report form  and submit it to Premier Research 
Pharmacovigilance (see contact [CONTACT_35659] 16.2.1 ). Premier Research  will notify the 
sponsor before the end of the next business day  after receipt of notification from the site . If the 
overdosage has  an associated AE or SAE, the site is to report and document the event as listed in 
this protocol  (see Section 16.1  for AEs, and  Section 16.2  for SAEs ). 
Known signs and symptoms  after acute overdosage  of d-MPH , resulting principally from 
overstimulation of the central nervous system and from excessive sympathomimetic effects, include 
vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by 
[CONTACT_355797]), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, 
tachycardia, palpi[INVESTIGATOR_814], cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous 
membranes  (Concerta® Extended Release Package Insert 2008, Focalin® Package Insert 2017, 
Focalin® XR Package Insert 2015, Ritalin® and Ritalin -SR® Package Insert 2015 ). Rhabdomyolysis 
has also been reported ( Ritalin® and Ritalin -SR® Package Insert 2015 ). 
Notifications of known incidences of subjects taking more than one caps ule of study drug per day 
(irrespective of the dose size) , which is considered misuse , will be provided by [CONTACT_728318].  
17. PREGNANCY  
If applicable ( see Section 1 3.1), females  with a positive pregnancy test will terminate the stu dy 
early. Within 24 hours of becoming aware of  pregnancy , the Investigator or designee will complete 
a paper pregnancy data collection form to be provided to Premier Research (see contact [CONTACT_728319] #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 92 of 97   May 09, 2019  
 in Section 16.2.1 ). Additionally, t he Investigator or designee will provide the paper pregnancy data 
collection form to the IRB within a time frame after the incident identification as required by [CONTACT_5040].  Premier Research will notify the sponsor before the end of the next business day afte r receipt 
of notification from the site . 
The pregnancy must be followed up until completion of the pregnancy in order to determine the fetal 
outcome. Any birth defects will be reported as SAEs. Every infant must be followed for 2 months after 
delivery.  
Pregnancy will not be considered an AE or SAE ; any pregnancy complication or termination of a 
pregnancy for medical reasons will be recorded as an AE or SAE. The site is to report and document 
AEs and SAEs  as listed in this protocol (see Section 16.1  for AEs,  and Section 16.2  for SAEs).  
18. PROTOCOL VIOLATIONS  
A protocol violation occurs when the subject, Investigator, or Sponsor fails to adhere to significant 
protocol requirements that materially (a) reduces the quality or completeness of the data, (b) makes 
the Informed Consent Form inaccurate, or (c) impacts a subject's safety, rights, or welfare. 
Examples of protocol violations may include the following:  
1. Inadequate or delinquent Informed Consent  
2. Inclusion/exclusion criteria not met 
3. Unreported serious adverse ev ents 
4. Multiple visits missed or outside permissible windows  
5. Materially inadequate record keepi[INVESTIGATOR_007]  
6. Intentional deviation from protocol, Good Clinical Practice, or regulations by [CONTACT_25617]  
7. Subject repeated non -compliance with study requirements  
 
It is th e Investigator ’s responsibility to report to the IRB of any Protocol Violation(s) according to 
the IRBs policy. Copy of the IRB submission will be filed in the site’s regulatory binder and in the 
Sponsor’s files.  
19. DATA MANAGEMENT AND RECORD KEEPI[INVESTIGATOR_1645]  
19.1. Data Man agement  
Data will be recorded at the site on e CRFs. All entries on a e CRF are ultimately the responsibility 
of the Site Investigator, who is expected to review each form for completeness, accuracy and 
legibility before signing. All forms must be filled out by [CONTACT_728320]. Errors should be lined out 
but not obliterated and the correction inserted, initialed and dated. A n eCRF must be completed for 
each participant for whom parental permission was obtained and who has given written  or verbal  
assent.  The eCRFs and source documents must be made available to the Sponsor and/or its 
representatives.  
Protocol Amendment #[ADDRESS_994805] source data (including records of subjects, subject visit logs, clinical observations and 
findings), correspondence with health authorities and IRB, consent forms, inventory of study 
product, Investigator’s curriculu m vitae, and monitor visit logs .  
The Investigator s should maintain the trial documents as required by [CONTACT_1729] , and 
should take measures to prevent accidental or premature destruction of documents. Clinical trial 
documents must be kept a t the clinical site  until written authorization is obtained from the Sponsor.  
19.3. Access to Source Data/Documents  
The Investigator s agree that the Sponsor, their representatives, the IRB, and representatives from 
worldwide regulatory agencies will have the rig ht, both during and after the clinical trial, to review 
and inspect pertinent medical records related to the clinical trial.  
20. QUALITY CONTROL AND QUALITY ASSURANCE  
By [CONTACT_12142], the Institution and the Sponsor agree to be responsible for implemen ting 
and maintaining quality control and quality assurance systems with written standard operating 
procedures to ensure that trials are conducted, and data are generated, documented, and reported in 
compliance with the protocol, accepted standards of Good Clinical Practice. (GCP), ICH and other 
applicable regulations.  
21. ETHICS AND GOOD CLINICAL PRACTICE COMPLIANCE  
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting trials that involve human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and wellbeing of trial subjects are 
protected, consistent with the principles that have their origin in the Declaration of Helsinki, and 
that the clinical trial data are credible. In this study, the 2008 version of the Declaration of Helsinki 
will be adhered to. It can be found on the website of The World Medical  Association: 
http://www.wma.net/en/30publications/10policies/b3/17c.pdf  
22. INSURANCE  
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsorship. This insurance policy is in accordance with local laws and require ments. The 
insurance of the Sponsor does not relieve the Site Investigator s and the other collaborators from 
maintaining their own liability insurance policy. An insurance certificate will be provided to the 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 94 of 97   May 09, 2019  
 IRB according to regulatory requirements.  
23. COMPLE TION OF STUDY  
The end of the study will be determined by [CONTACT_213926][INVESTIGATOR_728285] (see Section 8.6) . The 
IRB will be notified about the end of the study according to regulatory requirements.  
24. STUDY ADMINISTRATIVE INFORMATION  
24.1. Protocol Amendments  
Any a mendments to the study protocol considered to be a substantial amendment will be 
communicated to the Investigator by [CONTACT_1034]. All substantial protocol amendments will 
undergo the same review and approval pr ocess as the original protocol and may be implemented 
after it has been approved by [CONTACT_1201] , unless immediate implementation of the change is necessary 
for subject  safety. In this case, the situation must be doc umented and reported to the IRB  according 
to all relevant regulatory requirements . 
A protocol amendment is considered to be a substantial amendment if it is likely to affect the safety, 
physical, or mental integrity of subjects in the study; the scientific value of the study; the conduct 
or managemen t of the study; or the quality or safety of any Investigational Medicinal Product  used 
in the study. 
Any other minor changes to the protocol not considered to be substantial amendments will not need 
prior approval of the IRB and will be communicated to the  Investigator by [CONTACT_1034].  
  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 95 of 97   May 09, 2019  
 25. REFERENCES  
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth  
Edition (DSM -5). Arlington, VA,  American Psychiatric Association , 2013 . 
Busner J, Targum SD. The Clinical Global Impre ssions Scale: Applying a research tool in 
clinical practice. Psychiatry 4:28 –37, 2007.  
Challman TD , Lipsky JJ.  Methylpheni date: its pharmacology and uses (2000). Mayo Clin Proc. 
75(7):711- 21. 
Concerta® Extended Release [Package I nsert]. Janssen Pharmaceuticals, Inc. 20 08. 
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale -5 for Children and 
Adolescents: Checklists, Norms, and Clinical Interpretation. [LOCATION_001]: Guildford, 2016. 
Focalin® [Package I nsert]. [COMPANY_001] Pharmaceuticals Corpo ration . 2017. 
Focalin® XR [Package I nsert]. [COMPANY_001] Pharmaceuticals Corporation . 2015. 
Food and Drug Administration, Assessment of Abuse Potential of Drugs. (2017, January). Guidance 
for Industry, U.S. Department of Health and Human Services, Center for D rug Evaluation and 
Research, Washington, DC.  
Leonard BE , McCartan D, White J, King DJ.  Methylphenidate: a review of its 
neuropharmacological, neuropsychological and adverse clinical effects.  Hum Psychopharmacol. 
19:151 -80, 2004.  
Morton WA, Stockton GG. Met hylphenidate Abuse and Psychiatric Side Effects  (2000) . Primary 
Care Companion to The Journal of Clinical Psychiatry . 2:159 -164. 
Posner K, Brent D, Lucas C, Gould M, Stanley B , Brown G , Fisher P, Zelazny J, Burke A, Oquendo 
M, Mann J. Columbia -Suicide Severity Rating Scale (C -SSRS) Pediatric Baseline Version. New 
York, NY: The Research Foundation for Mental Hygiene, Inc., 2010 . 
Owens JA, Spi[INVESTIGATOR_50175] A, McGuinn M. The Children’s Sleep Habits Questionnaire (CSHQ): 
psychometric properties of a  survey instrument for school -aged children. Sleep , 2000a ; 23(8):1043–
51. 
Owens J, S pi[INVESTIGATOR_50175] A, McGuinn M, Nobile C. Sleep habits and sleep disturbance in school -aged 
children. Journal of Developmental and Behavioral Pediatrics, 2000b ; 21(1):27- 36. 
Ritalin® and Ritalin -SR® [Package I nsert]. [COMPANY_001] Pharmaceuticals Corporation . 2015. 
Sellers EM, Romach MK . Categorization of Abuse Potential -Related Adverse Events.  Clin 
Pharmacol Drug Dev. [ADDRESS_994806] 11. doi: 10.1002/cpdd.394. [Epub ahead of print] . 
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 96 of 97   May 09, 2019  
 Wilens TE, Bi ederman J. The stimulants. Psychi atric Clinics of North America. 15:191- 222, 
1992. 
Wilens T, Adler  LA, Adams  J, Sgambati  S, Rotrosen  J, Sawtelle  R, Utzinger  L and Fusillo S. 
Misuse and diversion of stimulants prescribed for ADHD: a syste matic review of the literature.  J 
Am Aca d Child Adolesc Psychiatry 47: 21- 31, 2008. 
  
Protocol Amendment #3 KP415.S01  CONFIDENTIAL  KemPharm, Inc.  
 
 
Page 97 of 97   May 09, 2019  
 Appendix A: Instructions for Oral Administration of Study Drug  
• Instructions for taking study drug as a whole capsule  
1. Swallow capsule whole with a cup  of water . The capsule needs to be swallowed whole 
(without crushing, cutting, crushing, chewing, opening, or dissolving) . Do not swallow the 
capsule without water.  
2. Take more sips of water as needed, up to approximately 8 ounces ( 240 mL ) of water in total.  
 
• Instructions for taking study drug with applesauce:  
1. Place approximately 1- 2 tablespoons (~ 15-30 mL) of applesauce into a clean cup.  
2. Carefully open the capsule and sprinkle the powder onto the applesauce. Discard the capsule 
shell in the garbage. 
3. Swallow the applesauce with study drug righ t away. Do not save the applesauce with study 
drug for later use.  
4. To make sure that the entire dose is taken, add more water  to the cup, swirl  and swallow the 
water  right away . 
5. Take more sips of water as needed , up to approximately 7 ounces (210 mL) of water in total.  
 
• Instructions for taking study drug with water:  
1. Place approximately 1- 2 tablespoons (~ 15-30 mL) of water into a clean cup. 
2. Carefully open the capsule and empty the powder  into the cup  of water.  Discard the capsule 
shell in the garbage. 
3. Gent ly swirl the container of water with study drug. 
4. Swallow the water with study drug right away. Do not save the water with study drug for 
later use.  
5. To make sure that the entire dose is taken, add more water  to the cup, swirl  and swallow the 
water  right awa y. 
6. Take more sips of water as needed , up to approximately 7 ounces (210 mL) of water in total.  
 